# ClaimBack agent logs: run `cgm-full-lifecycle`

Recorded from ClaimBack's real event logs (`events.jsonl`). Synthetic patient; the insurer's emails are SIMULATED by a scripted test harness. Logs contain placeholders such as `[PATIENT_NAME_1]` and counts, never identifiers. Model calls show model, effort, tokens, time and estimated list-price cost.

| Phase | Wall time | Model calls | Tokens in / out | Est. cost | Retries |
|---|---|---|---|---|---|
| Agent run | 9.5 min | 15 | 356,521 / 70,568 | $2.90 | 3 |

Legend: ▶ start · ✓ done · → handoff · ↻ retry (reason and what was fed back) · ⟲ revision loop · ! warning · ✗ error · `m:ss` since the phase started.

## Phase 1 · Agent run

166 events, starting 2026-10-15 13:43:45 UTC.

- `0:00` **orchestrator** ▶ new run cgm-full-lifecycle for case 'cgm-denial' · model claude-opus-5-5 · chaos mode: planned failures on first attempts
- `0:00` **orchestrator** · workflow: intake → planner → (policy ∥ evidence) → writer ⇄ (reviewer ∥ fact-checker) → packager
- `0:00` **intake** · received 3 documents: NOTES (335 words), DENIAL (434 words), POLICY (460 words) · offline reference library 438 words
- `0:00` **intake** ▶ intake_phi (attempt 1/3) · received the 3 raw documents (the only stage that sees identifiers)
- `0:06` **intake** · model call · claude-opus-5-5 · effort low · 4,532 in / 635 out tokens · 6.4s · $0.0308
- `0:06` **intake** ✓ intake_phi complete in 6.4s · found 13 identifier spellings: 3 PROVIDER_NAME, 3 PATIENT_ADDRESS, 1 PATIENT_NAME, 1 DATE_OF_BIRTH, 1 MEDICAL_RECORD_NUMBER, 1 PHONE, 1 MEMBER_ID, 1 GROUP_NUMBER, 1 OTHER_IDENTIFIER

  <details><summary>data</summary>

  ```json
  {
    "stage": "intake_phi",
    "attempt": 1,
    "duration_s": 6.44,
    "total_duration_s": 6.44,
    "validator": "passed",
    "output": {
      "identifier_spellings": 13,
      "by_category": {
        "PATIENT_NAME": 1,
        "DATE_OF_BIRTH": 1,
        "MEDICAL_RECORD_NUMBER": 1,
        "PROVIDER_NAME": 3,
        "PHONE": 1,
        "PATIENT_ADDRESS": 3,
        "MEMBER_ID": 1,
        "GROUP_NUMBER": 1,
        "OTHER_IDENTIFIER": 1
      },
      "distinct_people": 2,
      "values_logged": false
    }
  }
  ```

  </details>

- `0:06` **intake** ✓ redacted 13 identifier strings into 11 placeholders (3 PATIENT_ADDRESS, 1 OTHER_IDENTIFIER, 1 PROVIDER_NAME, 1 PHONE, 1 PATIENT_NAME, 1 MEMBER_ID, 1 GROUP_NUMBER, 1 MEDICAL_RECORD_NUMBER, 1 DATE_OF_BIRTH) · leak check passed · downstream agents see placeholders only

  <details><summary>data</summary>

  ```json
  {
    "strings_replaced": 13,
    "placeholders": [
      "[DATE_OF_BIRTH_1]",
      "[GROUP_NUMBER_1]",
      "[MEDICAL_RECORD_NUMBER_1]",
      "[MEMBER_ID_1]",
      "[OTHER_IDENTIFIER_1]",
      "[PATIENT_ADDRESS_1]",
      "[PATIENT_ADDRESS_2]",
      "[PATIENT_ADDRESS_3]",
      "[PATIENT_NAME_1]",
      "[PHONE_1]",
      "[PROVIDER_NAME_1]"
    ],
    "placeholders_by_category": {
      "PATIENT_ADDRESS": 3,
      "OTHER_IDENTIFIER": 1,
      "PROVIDER_NAME": 1,
      "PHONE": 1,
      "PATIENT_NAME": 1,
      "MEMBER_ID": 1,
      "GROUP_NUMBER": 1,
      "MEDICAL_RECORD_NUMBER": 1,
      "DATE_OF_BIRTH": 1
    },
    "leak_check": "passed",
    "redacted_documents": {
      "NOTES": 2422,
      "DENIAL": 2909,
      "POLICY": 3288
    },
    "identifier_map": "kept on local disk (phi_map.json), never sent to a model or logged"
  }
  ```

  </details>

- `0:06` **intake** ▶ intake_facts (attempt 1/3) · received 3 redacted documents
- `0:18` **intake** · model call · claude-opus-5-5 · effort low · 4,825 in / 1,345 out tokens · 12.0s · $0.0462
- `0:18` **intake** ✓ intake_facts complete in 12.0s · Evergreen Mutual Health Plan denied Continuous Glucose Monitor (CGM) system and sensors (E2103, A4239) on 2026-09-22 · reason MN-04 · 180-day appeal window

  <details><summary>data</summary>

  ```json
  {
    "stage": "intake_facts",
    "attempt": 1,
    "duration_s": 11.98,
    "total_duration_s": 11.98,
    "validator": "passed",
    "output": {
      "insurer_name": "Evergreen Mutual Health Plan",
      "denial_date": "2026-09-22",
      "request_or_claim_number": "[OTHER_IDENTIFIER_1]",
      "service_requested": "Continuous Glucose Monitor (CGM) system and sensors",
      "service_codes": [
        "E2103",
        "A4239"
      ],
      "denial_reason_code": "MN-04",
      "denial_reason_summary": "Denied as not medically necessary. The plan stated that Medical Policy MP-DME-031 requires intensive insulin therapy (3 or more daily injections or an insulin pump), and that the member uses only once-daily long-acting insulin. Note: the current policy (revised 01/01/2026) removed the 3+ injection requirement and now covers any insulin-treated member or members with documented problematic hypoglycemia. The denial appears to apply superseded criteria.",
      "policy_cited_by_insurer": "Evergreen Mutual Medical Policy MP-DME-031 (Continuous Glucose Monitoring)",
      "appeal_window_days": 180,
      "expedited_appeal_available": true,
      "diagnoses": [
        "E11.65 - Type 2 diabetes mellitus with hyperglycemia",
        "Z79.4 - Long-term (current) use of insulin",
        "Z79.84 - Long-term (current) use of oral hypoglycemic drugs (metformin, empagliflozin)",
        "E11.649 - Type 2 diabetes mellitus with hypoglycemia without coma (recurrent nocturnal level 2 hypoglycemia)",
        "E11.42 - Type 2 diabetes mellitus with diabetic polyneuropathy (peripheral neuropathy)"
      ],
      "current_treatment": [
        "Insulin glargine 32 units SC nightly (reduced from 36 units after 07/02/2026 hypoglycemic episode)",
        "Metformin 1000 mg PO twice daily",
        "Empagliflozin 25 mg PO daily",
        "Lisinopril 10 mg PO daily",
        "Atorvastatin 40 mg PO daily",
        "Fingerstick glucose monitoring 3-4 times daily"
      ],
      "clinical_summary": "65-year-old woman with type 2 diabetes since 2009, complicated by peripheral neuropathy. She has been on basal insulin glargine since 2024 after failing to reach goal on metformin and empagliflozin. She had two documented symptomatic nocturnal level 2 hypoglycemic episodes: 48 mg/dL on 07/02/2026 and 51 mg/dL on 08/19/2026. The second occurred despite a glargine dose reduction from 36 to 32 units. She lives alone. A1c worsened to 9.1% on 09/10/2026 (from 8.7% in 03/2026), and eGFR is 68. Hypoglycemia limits insulin titration. Fingerstick monitoring cannot detect nocturnal lows and is impaired by fingertip neuropathy. At the 09/10/2026 visit, the endocrinologist prescribed a therapeutic CGM per FDA labeling. The patient was trained by a diabetes educator that day and demonstrated sensor application and app use. The documentation appears to address current policy criteria I.A, I.B.1, I.B.2.a, I.C, I.D and I.E.",
      "missing_information": [
        "Copy of the original prior authorization request submitted 09/18/2026 and the records the plan reviewed",
        "Specific CGM device brand/model prescribed",
        "Glucose logs or meter download documenting the hypoglycemic episodes",
        "Confirmation of which version of policy MP-DME-031 the reviewer applied (the denial cites a 3+ injection requirement removed 01/01/2026)",
        "Letter of medical necessity from the treating endocrinologist",
        "Signed Appointment of Representative form if the clinic files on the member's behalf"
      ]
    }
  }
  ```

  </details>

- `0:18` **intake** → planner: case facts · Continuous Glucose Monitor (CGM) system and sensors denied (MN-04) on 2026-09-22 · 6 gaps noted

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "planner"
    ],
    "artifact": "CaseFacts",
    "chars": 3273
  }
  ```

  </details>

- `0:18` **planner** ▶ plan (attempt 1/3) · received the case facts (no documents)
- `1:10` **planner** · model call · claude-opus-5-5 · effort medium · 2,824 in / 5,040 out tokens · 52.6s · $0.1121
- `1:10` **planner** ✓ plan complete in 52.6s · merit strong · medical necessity · expedited appeal · 10 policy + 10 research questions · 8 risks

  <details><summary>data</summary>

  ```json
  {
    "stage": "plan",
    "attempt": 1,
    "duration_s": 52.58,
    "total_duration_s": 52.58,
    "validator": "none",
    "output": {
      "merit": "strong",
      "merit_rationale": "The denial rests on a 3+ daily injection or pump requirement that the facts say was removed from MP-DME-031 effective 01/01/2026, before the 09/2026 request. The current criteria cover any insulin-treated member or members with documented problematic hypoglycemia. The patient meets both routes independently. She is on daily basal glargine (Z79.4). She also has two documented symptomatic nocturnal level 2 events (48 and 51 mg/dL), the second after a dose reduction. She was prescribed a therapeutic CGM by an endocrinologist and was trained and demonstrated competence on 09/10/2026. The clinical summary says the record addresses current criteria I.A, I.B.1, I.B.2.a, I.C, I.D and I.E. A denial applying superseded criteria is a plain misapplication. The main caveat is documentation: the plan's reviewed records, glucose logs and an LMN are not yet in hand. We also need the full current policy text to confirm every criterion, not just the one the denial cited.",
      "alternatives": [
        "Have the endocrinologist's office call the plan for a peer-to-peer review or reconsideration. They should point out that the reviewer applied the pre-01/01/2026 version of MP-DME-031; this may reverse the denial faster than a formal appeal.",
        "Ask whether the plan covers CGMs under the pharmacy benefit instead of DME. Many plans do, sometimes with different criteria. If so, submit through the pharmacy channel at the same time.",
        "If the internal appeal is upheld, request independent external review. A denial based on superseded criteria is well suited to outside review.",
        "If the plan is a fully insured or state-regulated product, file a complaint with the state insurance regulator about the plan applying outdated medical policy.",
        "If the patient is actually enrolled in Medicare Advantage at age 65, cite CMS rules: MA plans must cover at least what Traditional Medicare covers. Medicare's CGM LCD covers insulin-treated patients or those with problematic hypoglycemia.",
        "Look into manufacturer patient assistance or cash-price programs for the prescribed CGM as a bridge while the appeal is pending. Note that the OTC CGMs currently sold are generally not labeled for people on insulin or at risk of hypoglycemia, so they are not an appropriate substitute here; confirm this with the prescriber.",
        "Meanwhile, the clinician may want to address nocturnal safety, for example a bedtime glucose check plan, a glucagon prescription, or insulin regimen review. This is clinical care, not a coverage route, and is the prescriber's decision."
      ],
      "denial_category": "medical_necessity",
      "appeal_type": "expedited",
      "appeal_type_rationale": "The facts point to a real risk of serious harm from delay. She has had recurrent symptomatic nocturnal level 2 hypoglycemia (<54 mg/dL), and it recurred even after a dose reduction. She lives alone, fingerstick testing cannot detect lows during sleep, and peripheral neuropathy impairs fingertip testing. Undetected nocturnal hypoglycemia in someone living alone can progress to level 3 events (seizure, injury, death). A standard pre-service timeline of up to 30 days or more prolongs that exposure, and hypoglycemia is also blocking needed insulin titration with A1c rising to 9.1%. The plan says expedited appeal is available. The request should include a statement from the treating endocrinologist certifying the urgency; under ACA/ERISA rules, a treating physician's certification generally compels expedited handling. If the plan declines expedited status, the appeal should proceed as standard with the same content.",
      "strategy": "Lead with the procedural error. The denial applied criteria (3+ injections/day or pump) that the plan removed from MP-DME-031 effective 01/01/2026. Quote the current policy's revision history and coverage language side by side with the denial letter. Then show criterion by criterion that the record meets the current version:\n(1) insulin-treated diabetes, via daily glargine since 2024; and independently\n(2) documented problematic hypoglycemia, via two symptomatic nocturnal level 2 events with dates and values, the second despite dose reduction;\n(3) prescribed by the treating endocrinologist for use per FDA labeling;\n(4) patient trained and demonstrated competence on 09/10/2026;\n(5) any visit-recency or other requirements in I.A–I.E, mapped to specific record pages.\nSupport this with clinical consensus: ADA Standards of Care recommend CGM for adults on any insulin, including basal-only, and for people with problematic hypoglycemia. RCT evidence such as the MOBILE trial shows benefit for basal-insulin type 2 patients. Add the specific safety rationale: she lives alone, has nocturnal lows undetectable by fingerstick, and has neuropathy impairing fingertip testing. Note that hypoglycemia is preventing titration while A1c worsens. Request expedited handling with physician certification. Ask the plan to identify the policy version applied and to provide the full claim file. Request that any reviewer be a board-certified endocrinologist or similar specialist. Before filing, gather the missing items:\n- the endocrinologist's LMN\n- meter/glucose logs or clinic notes documenting the 07/02 and 08/19 episodes\n- device brand/model\n- the original PA submission\n- a signed Appointment of Representative form if the clinic files\nPreserve external review rights.",
      "policy_questions": [
        "What is the full text of current MP-DME-031 (revised 01/01/2026), including every numbered criterion (I.A, I.B.1, I.B.2.a, I.C, I.D, I.E and any others)? What are its effective date and revision history, showing removal of the 3+ injection / pump requirement?",
        "Which version and effective date of MP-DME-031 did the reviewer actually apply, per the denial letter and claim file? Does the denial quote language that appears only in a superseded version?",
        "Under current criteria, is 'insulin-treated' satisfied by basal-only insulin (once-daily glargine)? Is there any minimum dose or duration requirement?",
        "How does the current policy define 'problematic hypoglycemia'? Is it level 2 (<54 mg/dL) recurring, or level 3? What documentation does it require: number of events, meter values, dates, symptoms, attempted regimen changes?",
        "Does the policy require a recent in-person or telehealth visit with the prescriber within a set timeframe, specialist prescribing, or documentation of patient/caregiver training and ability to use the device? Do the 09/10/2026 notes satisfy these?",
        "Does the policy distinguish therapeutic (non-adjunctive) CGM from adjunctive CGM? Are E2103 and A4239 the correct codes for the prescribed device under this plan, or is CGM routed to the pharmacy benefit?",
        "Does the plan's certificate of coverage or appeals procedure require it to apply the medical policy in effect on the date of the request or service? Does it address timelines and physician certification for expedited pre-service appeals?",
        "Is this plan fully insured, self-funded ERISA, or Medicare Advantage? This determines the external review pathway, the regulator, and whether Medicare coverage rules set a floor.",
        "Does the plan cover CGM under a pharmacy benefit with separate criteria or formulary placement?",
        "What are the reviewer qualifications for medical-necessity appeals? Can we request a same-specialty (endocrinology) reviewer?"
      ],
      "research_questions": [
        "What do the current ADA Standards of Care in Diabetes (Diabetes Technology section) recommend on CGM for adults with type 2 diabetes on basal insulin only, and for people with problematic or nocturnal hypoglycemia? What evidence grades are given?",
        "What did the MOBILE randomized trial (Martens et al., JAMA 2021) find about CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin, for A1c and time in range?",
        "What are the current Medicare LCD criteria for CGM (L33822, Glucose Monitors) after the 2023 revision? Do they cover any insulin-treated patient and patients with level 2 or level 3 problematic hypoglycemia? How is problematic hypoglycemia defined?",
        "How do the ADA and the International Hypoglycaemia Study Group define level 2 hypoglycemia (<54 mg/dL)? What is the clinical significance of recurrent nocturnal level 2 events, particularly for older adults and people living alone?",
        "What evidence shows that self-monitoring of blood glucose by fingerstick fails to detect nocturnal hypoglycemia compared with CGM?",
        "What do the AACE/ACE clinical practice guidelines on diabetes technology recommend about CGM for people on basal insulin and those at risk of hypoglycemia?",
        "What evidence or guidance supports CGM where peripheral neuropathy or reduced fingertip sensation or dexterity impairs fingerstick testing?",
        "How is hypoglycemia recognized as a barrier to insulin titration and glycemic control in type 2 diabetes? What evidence shows that CGM enables safer titration?",
        "What evidence links hypoglycemia in older adults with type 2 diabetes to falls, cardiovascular events, emergency visits, and mortality?",
        "What do the FDA labels of current therapeutic (non-adjunctive) CGM systems say about indications, including use for insulin dosing decisions and in type 2 diabetes?"
      ],
      "argument_hypotheses": [
        "The denial applied a superseded version of MP-DME-031. The 3+ injection or pump requirement was removed effective 01/01/2026, so the denial rests on a criterion that no longer exists and must be reversed.",
        "The member independently meets the current 'insulin-treated' criterion, because she has been on daily basal insulin glargine since 2024.",
        "The member independently meets the current 'problematic hypoglycemia' criterion. She had two symptomatic nocturnal level 2 events (48 and 51 mg/dL), and the second recurred despite reducing glargine from 36 to 32 units.",
        "All remaining current criteria are documented: endocrinologist prescription for therapeutic use per FDA labeling, training and demonstrated competence on 09/10/2026, and other items in I.A–I.E. The record needs to be mapped criterion by criterion.",
        "National clinical consensus supports the request. ADA Standards of Care recommend CGM for adults on basal insulin and for those with problematic hypoglycemia, and RCT evidence such as MOBILE shows benefit in basal-only type 2 diabetes.",
        "Fingerstick monitoring is clinically inadequate for this patient. It cannot detect nocturnal lows, neuropathy impairs fingertip testing, and she lives alone with no one to recognize nocturnal hypoglycemia.",
        "CGM is needed to break the cycle in which hypoglycemia prevents insulin titration while A1c worsens (8.7% to 9.1%). Denial therefore increases both acute hypoglycemia risk and long-term complication risk.",
        "If the plan is Medicare Advantage, it cannot apply criteria more restrictive than Traditional Medicare's CGM LCD. That LCD covers insulin-treated beneficiaries and those with problematic hypoglycemia."
      ],
      "risks": [
        "Documentation gap: the plan may say the hypoglycemic episodes are not substantiated if meter downloads, logs, or contemporaneous clinic notes with dates, values and symptoms are missing. Obtain these before filing.",
        "The original PA submission may have omitted the hypoglycemia history or training documentation. The plan could then argue the denial was correct on the record it had, even if the criteria cited were wrong. Review the 09/18/2026 submission.",
        "The facts flag the policy-version error but have not confirmed it from the plan's own documents. If the 01/01/2026 revision cannot be produced, or applies only to certain products, the core argument weakens. Obtain the current policy and revision history.",
        "The current policy may contain other requirements not yet confirmed, such as visit timing, specialist prescriber, or device-specific rules. The plan could shift to a new denial basis on appeal.",
        "The device brand/model is unknown. A coding mismatch (E2103/A4239 vs. the actual device) or a requirement to obtain CGM through the pharmacy benefit could cause a technical denial or re-routing.",
        "Expedited status may be refused without a treating physician's certification of urgency. That would slow the timeline, though it should not hurt the merits.",
        "If the clinic files without a signed Appointment of Representative form, the appeal may be rejected or delayed on procedural grounds.",
        "Plan type is unknown (commercial fully insured, self-funded ERISA, or Medicare Advantage at age 65). Using the wrong regulatory framework or external review route could cost time."
      ]
    }
  }
  ```

  </details>

- `1:11` **planner** · category=medical_necessity · appeal=expedited · The facts point to a real risk of serious harm from delay. She has had recurrent symptomatic nocturnal level 2 hypoglycemia (<54 mg/dL), and it recurred even after a dose reduction. She lives alone, fingerstick testing cannot detect lows during sleep, and peripheral neuropathy impairs fingertip testing. Undetected nocturnal hypoglycemia in someone living alone can progress to level 3 events (seizure, injury, death). A standard pre-service timeline of up to 30 days or more prolongs that exposure, and hypoglycemia is also blocking needed insulin titration with A1c rising to 9.1%. The plan says expedited appeal is available. The request should include a statement from the treating endocrinologist certifying the urgency; under ACA/ERISA rules, a treating physician's certification generally compels expedited handling. If the plan declines expedited status, the appeal should proceed as standard with the same content.
- `1:11` **planner** · merit: strong · The denial rests on a 3+ daily injection or pump requirement that the facts say was removed from MP-DME-031 effective 01/01/2026, before the 09/2026 request. The current criteria cover any insulin-treated member or members with documented problematic hypoglycemia. The patient meets both routes independently. She is on daily basal glargine (Z79.4). She also has two documented symptomatic nocturnal level 2 events (48 and 51 mg/dL), the second after a dose reduction. She was prescribed a therapeutic CGM by an endocrinologist and was trained and demonstrated competence on 09/10/2026. The clinical summary says the record addresses current criteria I.A, I.B.1, I.B.2.a, I.C, I.D and I.E. A denial applying superseded criteria is a plain misapplication. The main caveat is documentation: the plan's reviewed records, glucose logs and an LMN are not yet in hand. We also need the full current policy text to confirm every criterion, not just the one the denial cited.
- `1:11` **planner** · strategy: Lead with the procedural error. The denial applied criteria (3+ injections/day or pump) that the plan removed from MP-DME-031 effective 01/01/2026. Quote the current policy's revision history and coverage language side by side with the denial letter. Then show criterion by criterion that the record meets the current version:
(1) insulin-treated diabetes, via daily glargine since 2024; and independently
(2) documented problematic hypoglycemia, via two symptomatic nocturnal level 2 events with dates and values, the second despite dose reduction;
(3) prescribed by the treating endocrinologist for use per FDA labeling;
(4) patient trained and demonstrated competence on 09/10/2026;
(5) any visit-recency or other requirements in I.A–I.E, mapped to specific record pages.
Support this with clinical consensus: ADA Standards of Care recommend CGM for adults on any insulin, including basal-only, and for people with problematic hypoglycemia. RCT evidence such as the MOBILE trial shows benefit for basal-insulin type 2 patients. Add the specific safety rationale: she lives alone, has nocturnal lows undetectable by fingerstick, and has neuropathy impairing fingertip testing. Note that hypoglycemia is preventing titration while A1c worsens. Request expedited handling with physician certification. Ask the plan to identify the policy version applied and to provide the full claim file. Request that any reviewer be a board-certified endocrinologist or similar specialist. Before filing, gather the missing items:
- the endocrinologist's LMN
- meter/glucose logs or clinic notes documenting the 07/02 and 08/19 episodes
- device brand/model
- the original PA submission
- a signed Appointment of Representative form if the clinic files
Preserve external review rights.
- `1:11` **planner** · risk: Documentation gap: the plan may say the hypoglycemic episodes are not substantiated if meter downloads, logs, or contemporaneous clinic notes with dates, values and symptoms are missing. Obtain these before filing.
- `1:11` **planner** · risk: The original PA submission may have omitted the hypoglycemia history or training documentation. The plan could then argue the denial was correct on the record it had, even if the criteria cited were wrong. Review the 09/18/2026 submission.
- `1:11` **planner** · risk: The facts flag the policy-version error but have not confirmed it from the plan's own documents. If the 01/01/2026 revision cannot be produced, or applies only to certain products, the core argument weakens. Obtain the current policy and revision history.
- `1:11` **planner** · risk: The current policy may contain other requirements not yet confirmed, such as visit timing, specialist prescriber, or device-specific rules. The plan could shift to a new denial basis on appeal.
- `1:11` **planner** · risk: The device brand/model is unknown. A coding mismatch (E2103/A4239 vs. the actual device) or a requirement to obtain CGM through the pharmacy benefit could cause a technical denial or re-routing.
- `1:11` **planner** · risk: Expedited status may be refused without a treating physician's certification of urgency. That would slow the timeline, though it should not hurt the merits.
- `1:11` **planner** · risk: If the clinic files without a signed Appointment of Representative form, the appeal may be rejected or delayed on procedural grounds.
- `1:11` **planner** · risk: Plan type is unknown (commercial fully insured, self-funded ERISA, or Medicare Advantage at age 65). Using the wrong regulatory framework or external review route could cost time.
- `1:11` **planner** → policy_analyst: 10 questions · → evidence_researcher: 10 questions

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "policy_analyst",
      "evidence_researcher"
    ],
    "artifact": "RunPlan",
    "policy_questions": [
      "What is the full text of current MP-DME-031 (revised 01/01/2026), including every numbered criterion (I.A, I.B.1, I.B.2.a, I.C, I.D, I.E and any others)? What are its effective date and revision history, showing removal of the 3+ injection / pump requirement?",
      "Which version and effective date of MP-DME-031 did the reviewer actually apply, per the denial letter and claim file? Does the denial quote language that appears only in a superseded version?",
      "Under current criteria, is 'insulin-treated' satisfied by basal-only insulin (once-daily glargine)? Is there any minimum dose or duration requirement?",
      "How does the current policy define 'problematic hypoglycemia'? Is it level 2 (<54 mg/dL) recurring, or level 3? What documentation does it require: number of events, meter values, dates, symptoms, attempted regimen changes?",
      "Does the policy require a recent in-person or telehealth visit with the prescriber within a set timeframe, specialist prescribing, or documentation of patient/caregiver training and ability to use the device? Do the 09/10/2026 notes satisfy these?",
      "Does the policy distinguish therapeutic (non-adjunctive) CGM from adjunctive CGM? Are E2103 and A4239 the correct codes for the prescribed device under this plan, or is CGM routed to the pharmacy benefit?",
      "Does the plan's certificate of coverage or appeals procedure require it to apply the medical policy in effect on the date of the request or service? Does it address timelines and physician certification for expedited pre-service appeals?",
      "Is this plan fully insured, self-funded ERISA, or Medicare Advantage? This determines the external review pathway, the regulator, and whether Medicare coverage rules set a floor.",
      "Does the plan cover CGM under a pharmacy benefit with separate criteria or formulary placement?",
      "What are the reviewer qualifications for medical-necessity appeals? Can we request a same-specialty (endocrinology) reviewer?"
    ],
    "research_questions": [
      "What do the current ADA Standards of Care in Diabetes (Diabetes Technology section) recommend on CGM for adults with type 2 diabetes on basal insulin only, and for people with problematic or nocturnal hypoglycemia? What evidence grades are given?",
      "What did the MOBILE randomized trial (Martens et al., JAMA 2021) find about CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin, for A1c and time in range?",
      "What are the current Medicare LCD criteria for CGM (L33822, Glucose Monitors) after the 2023 revision? Do they cover any insulin-treated patient and patients with level 2 or level 3 problematic hypoglycemia? How is problematic hypoglycemia defined?",
      "How do the ADA and the International Hypoglycaemia Study Group define level 2 hypoglycemia (<54 mg/dL)? What is the clinical significance of recurrent nocturnal level 2 events, particularly for older adults and people living alone?",
      "What evidence shows that self-monitoring of blood glucose by fingerstick fails to detect nocturnal hypoglycemia compared with CGM?",
      "What do the AACE/ACE clinical practice guidelines on diabetes technology recommend about CGM for people on basal insulin and those at risk of hypoglycemia?",
      "What evidence or guidance supports CGM where peripheral neuropathy or reduced fingertip sensation or dexterity impairs fingerstick testing?",
      "How is hypoglycemia recognized as a barrier to insulin titration and glycemic control in type 2 diabetes? What evidence shows that CGM enables safer titration?",
      "What evidence links hypoglycemia in older adults with type 2 diabetes to falls, cardiovascular events, emergency visits, and mortality?",
      "What do the FDA labels of current therapeutic (non-adjunctive) CGM systems say about indications, including use for insulin dosing decisions and in type 2 diabetes?"
    ]
  }
  ```

  </details>

- `1:11` **orchestrator** · policy analyst and evidence researcher run in parallel
- `1:11` **policy_analyst** ▶ policy (attempt 1/3) · received 3 redacted documents, the case facts and 10 planner questions
- `1:11` **evidence_researcher** ▶ evidence_web (attempt 1/2) · received a de-identified clinical summary and 10 research questions
- `1:11` **policy_analyst** ↻ policy failed: [chaos] simulated API timeout · retrying in 2s with the same inputs

  <details><summary>data</summary>

  ```json
  {
    "stage": "policy",
    "attempt": 1,
    "reason": "[chaos] simulated API timeout",
    "duration_s": 0.0,
    "wait_s": 2,
    "next_attempt": 2,
    "fed_back_to_agent": null,
    "chaos": true
  }
  ```

  </details>

- `1:11` **evidence_researcher** ↻ evidence_web failed: [chaos] simulated web search outage · retrying in 2s with the same inputs

  <details><summary>data</summary>

  ```json
  {
    "stage": "evidence_web",
    "attempt": 1,
    "reason": "[chaos] simulated web search outage",
    "duration_s": 0.0,
    "wait_s": 2,
    "next_attempt": 2,
    "fed_back_to_agent": null,
    "chaos": true
  }
  ```

  </details>

- `1:13` **policy_analyst** ▶ policy (attempt 2/3) · received 3 redacted documents, the case facts and 10 planner questions
- `1:13` **evidence_researcher** ▶ evidence_web (attempt 2/2) · received a de-identified clinical summary and 10 research questions
- `1:13` **evidence_researcher** · web research: up to 6 searches, limited to 10 independent domains (government, journals, professional societies)
- `1:52` **policy_analyst** · model call · claude-opus-5-5 · effort high · 7,019 in / 4,542 out tokens · 39.7s · $0.1189
- `1:52` **policy_analyst** ✓ policy complete in 39.7s · Evergreen Mutual Health Plan Medical Policy MP-DME-031: Continuous Glucose Monitoring (CGM). Original effective date 07/01/2019; last revised 01/01/2026. The 01/01/2026 revision changed Criterion I.B, removing the requirement for three or more daily insulin injections and extending coverage to members using any insulin or members with documented problematic hypoglycemia. The 07/01/2023 review made no criteria changes. Section I (Personal/Therapeutic CGM) requires ALL of the following: A. diagnosis of diabetes mellitus (type 1, type 2, or other); B. at least ONE of: B.1 insulin-treated (any insulin regimen, including a single daily dose of basal/long-acting insulin), or B.2 documented problematic hypoglycemia, defined as either B.2.a recurrent level 2 events (<54 mg/dL) persisting despite multiple attempts to adjust medication or modify the treatment plan, or B.2.b at least one level 3 event (altered mental or physical state requiring third-party assistance); C. CGM prescribed in accordance with its FDA indications for use; D. member or caregiver trained or will be trained to use the device, as documented by the prescribing practitioner; E. within 6 months before ordering, the treating practitioner had an in-person or telehealth visit to evaluate diabetes control and determined that A–D are met. Section II (Continued Coverage) requires a visit every 6 months documenting adherence. Section III states CGM is not medically necessary when Section I is not met. Also relevant is Evidence of Coverage Section 9 (Appeals): 9.1 internal appeal within 180 days, standard pre-service decision within 30 days; 9.2 expedited decision within 72 hours; 9.3 authorized representative form; 9.4 external review within 4 months. The policy sets no minimum insulin dose or duration, no specialist-prescriber requirement, and no separate adjunctive-CGM criteria; Section I is titled 'Personal (Therapeutic) CGM'. The provided documents do not address pharmacy-benefit routing of CGM or the correctness of codes E2103/A4239.: 5/7 criteria met, 1 unclear, 1 not met · 5 discrepancies in the denial · merit strong

  <details><summary>data</summary>

  ```json
  {
    "stage": "policy",
    "attempt": 2,
    "duration_s": 39.72,
    "total_duration_s": 41.73,
    "validator": "none",
    "output": {
      "policy_identified": "Evergreen Mutual Health Plan Medical Policy MP-DME-031: Continuous Glucose Monitoring (CGM). Original effective date 07/01/2019; last revised 01/01/2026. The 01/01/2026 revision changed Criterion I.B, removing the requirement for three or more daily insulin injections and extending coverage to members using any insulin or members with documented problematic hypoglycemia. The 07/01/2023 review made no criteria changes. Section I (Personal/Therapeutic CGM) requires ALL of the following: A. diagnosis of diabetes mellitus (type 1, type 2, or other); B. at least ONE of: B.1 insulin-treated (any insulin regimen, including a single daily dose of basal/long-acting insulin), or B.2 documented problematic hypoglycemia, defined as either B.2.a recurrent level 2 events (<54 mg/dL) persisting despite multiple attempts to adjust medication or modify the treatment plan, or B.2.b at least one level 3 event (altered mental or physical state requiring third-party assistance); C. CGM prescribed in accordance with its FDA indications for use; D. member or caregiver trained or will be trained to use the device, as documented by the prescribing practitioner; E. within 6 months before ordering, the treating practitioner had an in-person or telehealth visit to evaluate diabetes control and determined that A–D are met. Section II (Continued Coverage) requires a visit every 6 months documenting adherence. Section III states CGM is not medically necessary when Section I is not met. Also relevant is Evidence of Coverage Section 9 (Appeals): 9.1 internal appeal within 180 days, standard pre-service decision within 30 days; 9.2 expedited decision within 72 hours; 9.3 authorized representative form; 9.4 external review within 4 months. The policy sets no minimum insulin dose or duration, no specialist-prescriber requirement, and no separate adjunctive-CGM criteria; Section I is titled 'Personal (Therapeutic) CGM'. The provided documents do not address pharmacy-benefit routing of CGM or the correctness of codes E2103/A4239.",
      "insurer_rationale": "Denied as not medically necessary (reason code MN-04). The denial states that MP-DME-031 requires intensive insulin therapy of three or more daily injections or an insulin pump, and that the member uses once-daily long-acting insulin only. The reviewer is listed as Plan Medical Director (Internal Medicine). The denial does not state which version or effective date of MP-DME-031 was applied.",
      "criteria": [
        {
          "id": "I.A",
          "criterion": "Member has a diagnosis of diabetes mellitus (type 1, type 2, or other).",
          "status": "met",
          "supporting_fact": "Type 2 diabetes mellitus diagnosed 2009, coded E11.65, with E11.649 and E11.42 also documented.",
          "sources": [
            "POLICY",
            "NOTES"
          ]
        },
        {
          "id": "I.B.1",
          "criterion": "Member is insulin-treated (any insulin regimen, including a single daily dose of basal/long-acting insulin).",
          "status": "met",
          "supporting_fact": "Insulin glargine 32 units SC nightly since 2024 (Z79.4). The denial itself confirms once-daily long-acting insulin use. Current policy expressly includes a single daily basal dose and sets no minimum dose or duration.",
          "sources": [
            "POLICY",
            "NOTES",
            "DENIAL"
          ]
        },
        {
          "id": "I.B.2.a",
          "criterion": "Documented problematic hypoglycemia: recurrent level 2 events (<54 mg/dL) persisting despite multiple attempts to adjust medication or modify the treatment plan (alternative to I.B.1; not required if I.B.1 is met).",
          "status": "unclear",
          "supporting_fact": "Two symptomatic nocturnal level 2 events are documented: 48 mg/dL on 07/02/2026 and 51 mg/dL on 08/19/2026. The second occurred despite a glargine reduction from 36 to 32 units. However, only one medication adjustment is documented, while the policy says 'multiple attempts'. Meter downloads or logs are not in the record. This pathway is supportive but unnecessary because I.B.1 independently satisfies I.B.",
          "sources": [
            "POLICY",
            "NOTES"
          ]
        },
        {
          "id": "I.B.2.b",
          "criterion": "History of at least one level 3 hypoglycemic event requiring third-party assistance (alternative; not required).",
          "status": "not_met",
          "supporting_fact": "Both episodes were self-treated, and no level 3 event is documented. Not required because I.B.1 is met.",
          "sources": [
            "POLICY",
            "NOTES"
          ]
        },
        {
          "id": "I.C",
          "criterion": "CGM is prescribed in accordance with its FDA indications for use.",
          "status": "met",
          "supporting_fact": "Plan item 1: 'Prescribe therapeutic CGM system with sensors (E2103 / A4239) per FDA labeling.' The specific device brand/model is not named in the record.",
          "sources": [
            "POLICY",
            "NOTES"
          ]
        },
        {
          "id": "I.D",
          "criterion": "Member or caregiver has been or will be trained to use the device, as documented by the prescribing practitioner.",
          "status": "met",
          "supporting_fact": "Note signed by the prescribing endocrinologist documents that the patient was trained by a diabetes educator on 09/10/2026 and demonstrated sensor application and app use.",
          "sources": [
            "POLICY",
            "NOTES"
          ]
        },
        {
          "id": "I.E",
          "criterion": "Within 6 months before ordering, the treating practitioner had an in-person or telehealth visit to evaluate diabetes control and determined criteria A–D are met.",
          "status": "met",
          "supporting_fact": "Telehealth plus in-office labs visit with the endocrinologist on 09/10/2026, 8 days before the 09/18/2026 request. The visit evaluated diabetes control (A1c 9.1%, hypoglycemia history, insulin regimen) and documented the diagnosis, insulin use, FDA-labeled prescription and training.",
          "sources": [
            "POLICY",
            "NOTES",
            "DENIAL"
          ]
        }
      ],
      "criteria_status": {
        "met": 5,
        "unclear": 1,
        "not_met": 1
      },
      "discrepancies": [
        "The denial applies superseded criteria. It cites a requirement of 'three (3) or more daily injections of insulin or use of an insulin pump.' The policy revision history states this requirement was REMOVED effective 01/01/2026. The request was dated 09/18/2026, more than eight months after the revision, so the cited language exists only in a pre-2026 version of MP-DME-031.",
        "The denial treats 'once-daily long-acting insulin only' as disqualifying. Current Criterion I.B.1 expressly covers 'any insulin regimen, including a single daily dose of basal/long-acting insulin.' The fact the denial relies on actually satisfies the current criterion.",
        "The denial does not address the alternative hypoglycemia pathway (I.B.2). The record documents two level 2 nocturnal events (48 and 51 mg/dL) despite a dose reduction.",
        "The denial does not address Criteria I.A, I.C, I.D or I.E, all of which are documented in the 09/10/2026 note.",
        "The denial does not identify the version or effective date of MP-DME-031 it applied, even though the policy carries a 01/01/2026 revision."
      ],
      "procedural_issues": [
        "The reviewer is listed as Plan Medical Director (Internal Medicine), while the request came from an endocrinologist. The provided plan documents do not specify reviewer qualifications for medical-necessity appeals. The appeal should request review by a same-specialty (endocrinology) clinician and should not rely on any stated plan requirement for this.",
        "Appeal-window wording differs. The denial says the appeal 'must be received within 180 calendar days of the date of this notice.' EOC 9.1 allows filing 'within 180 calendar days of receiving an adverse benefit determination.' The denial's wording is more restrictive. Filing well within 180 days of 09/22/2026 avoids any dispute.",
        "The denial offers the clinical criteria used free of charge. The appeal should request the exact version of MP-DME-031 and the claim file the reviewer relied on, to confirm the superseded version was applied.",
        "Plan type (fully insured, self-funded ERISA, or Medicare Advantage) is not stated in the documents. The denial and EOC route external review through the Oregon Division of Financial Regulation, which suggests a state-regulated plan, but this is not confirmed.",
        "The EOC excerpt does not state which policy version applies (date of request vs. date of service). Here the 01/01/2026 revision predates both the request and the visit, so the current version applies under either reading.",
        "Expedited appeal (72 hours) is described consistently in the denial and EOC 9.2. Neither document states a physician-certification requirement. Standard pre-service appeals are decided within 30 days (EOC 9.1).",
        "If the clinic files the appeal, a signed Appointment of Representative form is required (EOC 9.3).",
        "No missed deadline is apparent: the request was dated 09/18/2026 and the denial issued 09/22/2026. Appeal rights, external review rights, and consumer assistance contacts are included in the denial."
      ],
      "strongest_policy_argument": "The denial rests entirely on a criterion that no longer exists. MP-DME-031's revision history states that, effective 01/01/2026, 'Requirement for three or more daily insulin injections REMOVED,' and current Criterion I.B.1 covers members on 'any insulin regimen, including a single daily dose of basal/long-acting insulin.' The member's nightly insulin glargine, which the denial itself acknowledges, therefore satisfies I.B.1. The 09/10/2026 endocrinology visit, 8 days before the 09/18/2026 request, documents all remaining required criteria: type 2 diabetes (I.A), a CGM prescribed per FDA labeling (I.C), training with demonstrated competence (I.D), and a qualifying visit evaluating diabetes control (I.E). Independently, two documented symptomatic level 2 nocturnal hypoglycemic events (48 and 51 mg/dL) persisting despite a glargine dose reduction support the alternative I.B.2.a pathway.",
      "merit": "strong",
      "merit_rationale": "Every required criterion under the current policy (I.A, I.B via I.B.1, I.C, I.D, I.E) is met by the 09/10/2026 documentation. The denial also misapplies the policy by citing a 3+ injection/pump requirement removed effective 01/01/2026. The only unclear item, I.B.2.a ('multiple attempts' to adjust medication, given one documented dose reduction), is an alternative pathway and is not required."
    }
  }
  ```

  </details>

- `3:45` **evidence_researcher** · model call · claude-opus-5-5 · effort medium · 199,798 in / 11,510 out tokens · 6 web searches · 152.8s · $1.0894
- `3:45` **evidence_researcher** · web search: ADA Standards of Care diabetes technology CGM basal insulin recommendation 7.15
- `3:45` **evidence_researcher** · web search returned 10 pages: diabetesjournals.org, pmc.ncbi.nlm.nih.gov
- `3:45` **evidence_researcher** · web search: ADA Standards of Care diabetes technology CGM basal insulin
- `3:45` **evidence_researcher** · web search returned 9 pages: diabetesjournals.org, pmc.ncbi.nlm.nih.gov, cdn.clinicaltrials.gov
- `3:45` **evidence_researcher** · web search: Diabetes Technology Standards of Care in Diabetes 2026 CGM recommendation
- `3:45` **evidence_researcher** · web search returned 9 pages: aafp.org, diabetesjournals.org, pmc.ncbi.nlm.nih.gov
- `3:45` **evidence_researcher** · web search: 7. Diabetes Technology: Standards of Care in Diabetes—2026 recommendation 7.15 CGM onset insulin therapy grade
- `3:45` **evidence_researcher** · web search returned 9 pages: diabetesjournals.org, pmc.ncbi.nlm.nih.gov
- `3:45` **evidence_researcher** · web search: "Standards of Care in Diabetes—2026" CGM "at diabetes onset" insulin therapy recommendation grade A
- `3:45` **evidence_researcher** · web search returned 9 pages: diabetesjournals.org, aafp.org, pmc.ncbi.nlm.nih.gov, cdn.clinicaltrials.gov, ncbi.nlm.nih.gov, arxiv.org
- `3:45` **evidence_researcher** · web search: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026 CGM hypoglycemia recommendation level 2
- `3:45` **evidence_researcher** · web search returned 9 pages: diabetesjournals.org, pmc.ncbi.nlm.nih.gov
- `3:45` **evidence_researcher** · research notes: 1,844 words handed to the structuring step
- `4:07` **evidence_researcher** · model call · claude-opus-5-5 · effort low · 5,955 in / 2,449 out tokens · 21.3s · $0.0728
- `4:07` **evidence_researcher** ✓ evidence_web complete in 174.1s · 5 sources (web search): EV-1 American Diabetes Association; EV-2 American Diabetes Association; EV-3 American Diabetes Association; EV-4 American Diabetes Association (via PubMed Central); EV-5 Centers for Medicare & Medicaid Services

  <details><summary>data</summary>

  ```json
  {
    "stage": "evidence_web",
    "attempt": 2,
    "duration_s": 174.14,
    "total_duration_s": 176.16,
    "validator": "none",
    "output": {
      "mode": "web search",
      "sources": [
        {
          "id": "EV-1",
          "title": "7. Diabetes Technology: Standards of Care in Diabetes—2026 (Diabetes Care 49(Suppl 1):S150)",
          "publisher": "American Diabetes Association",
          "url": "https://diabetesjournals.org/care/article/49/Supplement_1/S150/163922/7-Diabetes-Technology-Standards-of-Care-in",
          "finding": "Recommendation 7.15 recommends CGM from diabetes onset onward for children, adolescents, and adults on insulin therapy (Grade A), on noninsulin therapies that can cause hypoglycemia (Grade C), and on any treatment where CGM helps management (Grade C). Recommendation 7.5 says people using CGM should have continued access to devices across third-party payors regardless of age or A1C (Grade E). In 2024, Rec. 7.15 said CGM 'should be offered' to adults on basal insulin. In 2026 the wording changed to 'recommended.' Section 9, Rec. 9.25, was updated to match.",
          "relevance": "This is the primary guideline support. The patient is on basal insulin, so the Grade A insulin-therapy recommendation applies directly. Rec. 7.5 also counters any payer restriction based on age or A1C."
        },
        {
          "id": "EV-2",
          "title": "Summary of Revisions: Standards of Care in Diabetes—2026",
          "publisher": "American Diabetes Association",
          "url": "https://diabetesjournals.org/care/article/49/Supplement_1/S6/163930/Summary-of-Revisions-Standards-of-Care-in-Diabetes",
          "finding": "The ADA summary of 2026 changes states that CGM benefits have been shown regardless of age, sex, education or income level, or baseline diabetes characteristics.",
          "relevance": "Shows that CGM benefit is not limited to particular subgroups. This supports coverage for an older adult on basal insulin."
        },
        {
          "id": "EV-3",
          "title": "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026",
          "publisher": "American Diabetes Association",
          "url": "https://diabetesjournals.org/care/article/49/Supplement_1/S132/163927/6-Glycemic-Goals-Hypoglycemia-and-Hyperglycemic",
          "finding": "The 2026 text says CGM is particularly useful for people with diabetes at risk for hypoglycemia. For older adults with complex or intermediate health, the CGM targets allow more time high (time above 250 mg/dL under 10%) because hypoglycemia is the greater danger. Table 6.4 defines level 2 hypoglycemia as glucose below 54 mg/dL (3.0 mmol/L).",
          "relevance": "The patient's readings of 48 and 51 mg/dL meet the ADA definition of level 2 hypoglycemia. The guideline identifies people at risk for hypoglycemia, especially older adults, as a group for whom CGM is particularly useful."
        },
        {
          "id": "EV-4",
          "title": "6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024",
          "publisher": "American Diabetes Association (via PubMed Central)",
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10725808/",
          "finding": "The 2024 edition's Rec. 6.11d stated that CGM is beneficial and recommended for people at high risk for hypoglycemia (Grade A). Rec. 6.15 stated that one or more level 2 or 3 hypoglycemia episodes should prompt reevaluation of the treatment plan (Grade E).",
          "relevance": "This supports the hypoglycemia argument. However, it is the 2024 edition. The researcher could not confirm the 2026 recommendation number or wording, so check the 2026 Section 6 before citing this."
        },
        {
          "id": "EV-5",
          "title": "Local Coverage Determination L33822: Glucose Monitors",
          "publisher": "Centers for Medicare & Medicaid Services",
          "url": "https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822",
          "finding": "[UNVERIFIED — the researcher reported this from memory] CGM is covered when the patient has diabetes, has been trained to use the device, the CGM is prescribed according to its FDA indications, and a qualifying visit occurred within the prior 6 months. The patient must also meet either (A) insulin-treated, including basal-only, or (B) problematic hypoglycemia. Problematic hypoglycemia means recurrent level 2 events despite more than one attempt to adjust treatment, or one level 3 event.",
          "relevance": "The patient appears to qualify under the insulin-treated criterion. The hypoglycemia criterion may not be met, because the record shows only one medication adjustment. Lead with the insulin criterion. Verify the current LCD text before citing."
        }
      ],
      "gaps": [
        "The current text of LCD L33822 is unverified. Does it still cover basal-only insulin, and does it match the payer's numbered criteria?",
        "Does the chart document more than one medication or treatment-plan adjustment, which LCD criterion 4.B(a) requires?",
        "The 2026 ADA Section 6 hypoglycemia recommendation (the successor to 2024 Rec. 6.11d) has not been confirmed: number, wording, and grade are unknown.",
        "The 2026 ADA Section 13 (Older Adults) CGM recommendation number and grade have not been confirmed.",
        "The MOBILE trial (JAMA 2021) was excluded because Dexcom funded it. Is there independent RCT evidence for CGM in type 2 diabetes treated with basal insulin?",
        "Several unverified sources had no URL in the notes, so they could not be included. These are the International Hypoglycaemia Study Group 2017, the Agiostratidou 2017 consensus, Munshi 2011, Gehlaut 2015, the AACE 2021/2022 guidelines, Cryer, the GAPP survey, DIAMOND, ADVANCE, ACCORD, Geller 2014, Lipska 2014, Whitmer 2009, and Johnston 2012. Each needs to be located and verified.",
        "Current FDA labels for therapeutic CGMs (non-adjunctive use, insulin users) need to be retrieved from accessdata.fda.gov. Confirm that the over-the-counter devices (Stelo, Lingo) are not indicated for insulin users.",
        "No trial was found that studied CGM specifically in people with fingertip neuropathy or dexterity limits. This point depends on the clinician's documentation."
      ]
    }
  }
  ```

  </details>

- `4:07` **policy_analyst** · criterion I.A met: Member has a diagnosis of diabetes mellitus (type 1, type 2, or other). [POLICY, NOTES]
- `4:07` **policy_analyst** · criterion I.B.1 met: Member is insulin-treated (any insulin regimen, including a single daily dose of basal/long-acting insulin). [POLICY, NOTES, DENIAL]
- `4:07` **policy_analyst** · criterion I.B.2.a unclear: Documented problematic hypoglycemia: recurrent level 2 events (<54 mg/dL) persisting despite multiple attempts to adjust medication or modify the treatment plan (alternative to I.B.1; not required if I.B.1 is met). [POLICY, NOTES]
- `4:07` **policy_analyst** · criterion I.B.2.b not met: History of at least one level 3 hypoglycemic event requiring third-party assistance (alternative; not required). [POLICY, NOTES]
- `4:07` **policy_analyst** · criterion I.C met: CGM is prescribed in accordance with its FDA indications for use. [POLICY, NOTES]
- `4:07` **policy_analyst** · criterion I.D met: Member or caregiver has been or will be trained to use the device, as documented by the prescribing practitioner. [POLICY, NOTES]
- `4:07` **policy_analyst** · criterion I.E met: Within 6 months before ordering, the treating practitioner had an in-person or telehealth visit to evaluate diabetes control and determined criteria A–D are met. [POLICY, NOTES, DENIAL]
- `4:07` **policy_analyst** · discrepancy: The denial applies superseded criteria. It cites a requirement of 'three (3) or more daily injections of insulin or use of an insulin pump.' The policy revision history states this requirement was REMOVED effective 01/01/2026. The request was dated 09/18/2026, more than eight months after the revision, so the cited language exists only in a pre-2026 version of MP-DME-031.
- `4:07` **policy_analyst** · discrepancy: The denial treats 'once-daily long-acting insulin only' as disqualifying. Current Criterion I.B.1 expressly covers 'any insulin regimen, including a single daily dose of basal/long-acting insulin.' The fact the denial relies on actually satisfies the current criterion.
- `4:07` **policy_analyst** · discrepancy: The denial does not address the alternative hypoglycemia pathway (I.B.2). The record documents two level 2 nocturnal events (48 and 51 mg/dL) despite a dose reduction.
- `4:07` **policy_analyst** · discrepancy: The denial does not address Criteria I.A, I.C, I.D or I.E, all of which are documented in the 09/10/2026 note.
- `4:07` **policy_analyst** · discrepancy: The denial does not identify the version or effective date of MP-DME-031 it applied, even though the policy carries a 01/01/2026 revision.
- `4:07` **policy_analyst** · procedural issue: The reviewer is listed as Plan Medical Director (Internal Medicine), while the request came from an endocrinologist. The provided plan documents do not specify reviewer qualifications for medical-necessity appeals. The appeal should request review by a same-specialty (endocrinology) clinician and should not rely on any stated plan requirement for this.
- `4:07` **policy_analyst** · procedural issue: Appeal-window wording differs. The denial says the appeal 'must be received within 180 calendar days of the date of this notice.' EOC 9.1 allows filing 'within 180 calendar days of receiving an adverse benefit determination.' The denial's wording is more restrictive. Filing well within 180 days of 09/22/2026 avoids any dispute.
- `4:07` **policy_analyst** · procedural issue: The denial offers the clinical criteria used free of charge. The appeal should request the exact version of MP-DME-031 and the claim file the reviewer relied on, to confirm the superseded version was applied.
- `4:07` **policy_analyst** · procedural issue: Plan type (fully insured, self-funded ERISA, or Medicare Advantage) is not stated in the documents. The denial and EOC route external review through the Oregon Division of Financial Regulation, which suggests a state-regulated plan, but this is not confirmed.
- `4:07` **policy_analyst** · procedural issue: The EOC excerpt does not state which policy version applies (date of request vs. date of service). Here the 01/01/2026 revision predates both the request and the visit, so the current version applies under either reading.
- `4:07` **policy_analyst** · procedural issue: Expedited appeal (72 hours) is described consistently in the denial and EOC 9.2. Neither document states a physician-certification requirement. Standard pre-service appeals are decided within 30 days (EOC 9.1).
- `4:07` **policy_analyst** · procedural issue: If the clinic files the appeal, a signed Appointment of Representative form is required (EOC 9.3).
- `4:07` **policy_analyst** · procedural issue: No missed deadline is apparent: the request was dated 09/18/2026 and the denial issued 09/22/2026. Appeal rights, external review rights, and consumer assistance contacts are included in the denial.
- `4:07` **policy_analyst** · merit: strong · Every required criterion under the current policy (I.A, I.B via I.B.1, I.C, I.D, I.E) is met by the 09/10/2026 documentation. The denial also misapplies the policy by citing a 3+ injection/pump requirement removed effective 01/01/2026. The only unclear item, I.B.2.a ('multiple attempts' to adjust medication, given one documented dose reduction), is an alternative pathway and is not required.
- `4:07` **policy_analyst** → writer: 5/7 criteria met

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "writer"
    ],
    "artifact": "PolicyAnalysis",
    "chars": 10054
  }
  ```

  </details>

- `4:07` **evidence_researcher** · EV-1: 7. Diabetes Technology: Standards of Care in Diabetes—2026 (Diabetes Care 49(Suppl 1):S150) (American Diabetes Association) https://diabetesjournals.org/care/article/49/Supplement_1/S150/163922/7-Diabetes-Technology-Standards-of-Care-in
- `4:07` **evidence_researcher** · EV-2: Summary of Revisions: Standards of Care in Diabetes—2026 (American Diabetes Association) https://diabetesjournals.org/care/article/49/Supplement_1/S6/163930/Summary-of-Revisions-Standards-of-Care-in-Diabetes
- `4:07` **evidence_researcher** · EV-3: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026 (American Diabetes Association) https://diabetesjournals.org/care/article/49/Supplement_1/S132/163927/6-Glycemic-Goals-Hypoglycemia-and-Hyperglycemic
- `4:07` **evidence_researcher** · EV-4: 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024 (American Diabetes Association (via PubMed Central)) https://pmc.ncbi.nlm.nih.gov/articles/PMC10725808/
- `4:07` **evidence_researcher** · EV-5: Local Coverage Determination L33822: Glucose Monitors (Centers for Medicare & Medicaid Services) https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33822
- `4:07` **evidence_researcher** · gap: The current text of LCD L33822 is unverified. Does it still cover basal-only insulin, and does it match the payer's numbered criteria?
- `4:07` **evidence_researcher** · gap: Does the chart document more than one medication or treatment-plan adjustment, which LCD criterion 4.B(a) requires?
- `4:07` **evidence_researcher** · gap: The 2026 ADA Section 6 hypoglycemia recommendation (the successor to 2024 Rec. 6.11d) has not been confirmed: number, wording, and grade are unknown.
- `4:07` **evidence_researcher** · gap: The 2026 ADA Section 13 (Older Adults) CGM recommendation number and grade have not been confirmed.
- `4:07` **evidence_researcher** · gap: The MOBILE trial (JAMA 2021) was excluded because Dexcom funded it. Is there independent RCT evidence for CGM in type 2 diabetes treated with basal insulin?
- `4:07` **evidence_researcher** · gap: Several unverified sources had no URL in the notes, so they could not be included. These are the International Hypoglycaemia Study Group 2017, the Agiostratidou 2017 consensus, Munshi 2011, Gehlaut 2015, the AACE 2021/2022 guidelines, Cryer, the GAPP survey, DIAMOND, ADVANCE, ACCORD, Geller 2014, Lipska 2014, Whitmer 2009, and Johnston 2012. Each needs to be located and verified.
- `4:07` **evidence_researcher** · gap: Current FDA labels for therapeutic CGMs (non-adjunctive use, insulin users) need to be retrieved from accessdata.fda.gov. Confirm that the over-the-counter devices (Stelo, Lingo) are not indicated for insulin users.
- `4:07` **evidence_researcher** · gap: No trial was found that studied CGM specifically in people with fingertip neuropathy or dexterity limits. This point depends on the clinician's documentation.
- `4:07` **evidence_researcher** → writer: 5 sources

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "writer"
    ],
    "artifact": "EvidencePack",
    "chars": 5770
  }
  ```

  </details>

- `4:07` **writer** ▶ draft_1 (attempt 1/3) · received documents, facts, plan, policy analysis, evidence
- `4:07` **writer** ↻ draft_1 failed: [chaos] simulated malformed handoff (claim cites unknown source EV-99) · retrying in 2s with the same inputs

  <details><summary>data</summary>

  ```json
  {
    "stage": "draft_1",
    "attempt": 1,
    "reason": "[chaos] simulated malformed handoff (claim cites unknown source EV-99)",
    "duration_s": 0.0,
    "wait_s": 2,
    "next_attempt": 2,
    "fed_back_to_agent": null,
    "chaos": true
  }
  ```

  </details>

- `4:09` **writer** ▶ draft_1 (attempt 2/3) · received documents, facts, plan, policy analysis, evidence
- `5:20` **writer** · model call · claude-opus-5-5 · effort high · 16,912 in / 8,869 out tokens · 71.4s · $0.2450
- `5:20` **writer** ✓ draft_1 complete in 71.4s · 1,304 words · 27 sourced claims · cites DENIAL×9, EV-1×1, EV-2×1, EV-3×2, NOTES×11, POLICY×7

  <details><summary>data</summary>

  ```json
  {
    "stage": "draft_1",
    "attempt": 2,
    "duration_s": 71.38,
    "total_duration_s": 73.38,
    "validator": "passed",
    "output": {
      "subject_line": "Request for Expedited Internal Appeal: Denial of Therapeutic CGM (HCPCS E2103 / A4239), Claim/Request No. [OTHER_IDENTIFIER_1], Member ID [MEMBER_ID_1]",
      "words": 1304,
      "claims": [
        {
          "id": "C1",
          "text": "Evergreen Mutual issued a Notice of Adverse Benefit Determination dated September 22, 2026, denying the CGM system and sensors (HCPCS E2103 / A4239) as not medically necessary, reason code MN-04.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C2",
          "text": "The requesting provider is [PROVIDER_NAME_1] (Endocrinology), Willamette Valley Endocrine Associates; the request was dated September 18, 2026.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C3",
          "text": "The denial states MP-DME-031 requires three or more daily insulin injections or an insulin pump and that the member uses a once-daily long-acting insulin only.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C4",
          "text": "The MP-DME-031 revision history states that effective 01/01/2026 the requirement for three or more daily insulin injections was removed, coverage was extended to members using any insulin or with documented problematic hypoglycemia, and the revision was made to align with updated national coverage criteria and professional society guidelines.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C5",
          "text": "Current Criterion I.B.1 covers members who are insulin-treated under any insulin regimen, including a single daily dose of basal/long-acting insulin.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C6",
          "text": "Section I requires all of Criteria A through E to be met.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C7",
          "text": "The patient has type 2 diabetes diagnosed in 2009 (E11.65), diabetic peripheral neuropathy (E11.42), and hypoglycemia (E11.649).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C8",
          "text": "The patient takes insulin glargine 32 units nightly, started in 2024 after failure to reach goal on metformin and empagliflozin (Z79.4).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C9",
          "text": "The endocrinologist prescribed a therapeutic CGM system with sensors (E2103 / A4239) per FDA labeling.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C10",
          "text": "On 09/10/2026 a diabetes educator trained the patient on the device and she demonstrated sensor application and app use, documented in the note electronically signed by the prescribing endocrinologist.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C11",
          "text": "The 09/10/2026 visit was a telehealth visit with in-office labs, eight days before the 09/18/2026 request, and evaluated A1c, hypoglycemia history and insulin regimen; Criterion I.E requires such a visit within six months before ordering.",
          "sources": [
            "NOTES",
            "DENIAL",
            "POLICY"
          ]
        },
        {
          "id": "C12",
          "text": "Documented nocturnal hypoglycemia: 48 mg/dL at 3:10 AM on 07/02/2026 and 51 mg/dL at 2:45 AM on 08/19/2026, both symptomatic and self-treated; two episodes occurred in the past three months.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C13",
          "text": "The glargine dose was reduced from 36 to 32 units after the first episode, and the second episode occurred despite the reduction.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C14",
          "text": "Criterion I.B.2 defines problematic hypoglycemia to include recurrent level 2 events with glucose below 54 mg/dL.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C15",
          "text": "The ADA defines level 2 hypoglycemia as glucose below 54 mg/dL.",
          "sources": [
            "EV-3"
          ]
        },
        {
          "id": "C16",
          "text": "A1c was 9.1% on 09/10/2026, up from 8.7% in 03/2026.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C17",
          "text": "Nocturnal hypoglycemia limits further insulin titration; fingerstick monitoring is inadequate to detect nocturnal lows and is impaired by neuropathy (reduced fingertip sensation).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C18",
          "text": "The patient lives alone.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C19",
          "text": "The plan is to use CGM data to safely titrate basal insulin and reduce hypoglycemia risk, with follow-up in 3 months to review CGM data and adherence.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C20",
          "text": "ADA Standards of Care 2026 Recommendation 7.15 recommends CGM for adults on insulin therapy (Grade A); the 2026 wording changed from 'should be offered' (2024) to 'recommended' for adults on basal insulin.",
          "sources": [
            "EV-1"
          ]
        },
        {
          "id": "C21",
          "text": "ADA 2026 Section 6 states CGM is particularly useful for people at risk for hypoglycemia and sets CGM targets for older adults with complex or intermediate health that reflect the greater danger of hypoglycemia.",
          "sources": [
            "EV-3"
          ]
        },
        {
          "id": "C22",
          "text": "The ADA 2026 Summary of Revisions states CGM benefits have been shown regardless of age, sex, education or income level, or baseline diabetes characteristics.",
          "sources": [
            "EV-2"
          ]
        },
        {
          "id": "C23",
          "text": "The denial notice states the member may request, free of charge, copies of all documents and the clinical criteria used.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C24",
          "text": "The denial was reviewed by a Plan Medical Director (Internal Medicine).",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C25",
          "text": "Expedited appeals are decided within 72 hours where the standard timeframe could seriously jeopardize health; standard pre-service appeals are decided within 30 calendar days.",
          "sources": [
            "POLICY",
            "DENIAL"
          ]
        },
        {
          "id": "C26",
          "text": "If the denial is upheld, the member may request independent external review through the Oregon Division of Financial Regulation.",
          "sources": [
            "DENIAL",
            "POLICY"
          ]
        },
        {
          "id": "C27",
          "text": "Appeals are sent to Evergreen Mutual Health Plan - Appeals and Grievances, PO Box 4415, Portland, OR 97208, fax 1-800-555-0177.",
          "sources": [
            "DENIAL"
          ]
        }
      ],
      "citations_per_source": {
        "DENIAL": 9,
        "POLICY": 7,
        "NOTES": 11,
        "EV-3": 2,
        "EV-1": 1,
        "EV-2": 1
      },
      "enclosures": [
        "Notice of Adverse Benefit Determination, Evergreen Mutual Health Plan, dated September 22, 2026",
        "Willamette Valley Endocrine Associates progress note dated 09/10/2026",
        "Evergreen Mutual Medical Policy MP-DME-031 (last revised 01/01/2026) and Evidence of Coverage Section 9 excerpt"
      ]
    }
  }
  ```

  </details>

- `5:20` **writer** → reviewer + fact_checker: draft 1 (1304 words, 27 claims)

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "reviewer",
      "fact_checker"
    ],
    "artifact": "AppealDraft",
    "round": 1
  }
  ```

  </details>

- `5:20` **orchestrator** · reviewer and fact checker check draft 1 in parallel
- `5:20` **reviewer** ▶ review_1 (attempt 1/3) · received draft 1, the documents and the policy analysis
- `5:20` **fact_checker** ▶ factcheck_1 (attempt 1/3) · received draft 1's 27 claims and every cited source
- `5:43` **fact_checker** · model call · claude-opus-5-5 · effort medium · 11,662 in / 2,774 out tokens · 22.7s · $0.1021
- `5:43` **fact_checker** ✓ factcheck_1 complete in 22.7s · 27/27 claims verified · 0 unsupported · 0 untracked statements

  <details><summary>data</summary>

  ```json
  {
    "stage": "factcheck_1",
    "attempt": 1,
    "duration_s": 22.72,
    "total_duration_s": 22.73,
    "validator": "none",
    "output": {
      "verified": 27,
      "claims": 27,
      "checks": [
        {
          "claim": "C1",
          "verdict": "supported",
          "explanation": "DENIAL is dated September 22, 2026. It denies the CGM system and sensors (E2103 / A4239) as not medically necessary under reason code MN-04."
        },
        {
          "claim": "C2",
          "verdict": "supported",
          "explanation": "DENIAL lists the requesting provider as [PROVIDER_NAME_1] (Endocrinology), Willamette Valley Endocrine Associates, and the date of request as September 18, 2026."
        },
        {
          "claim": "C3",
          "verdict": "supported",
          "explanation": "DENIAL states that MP-DME-031 requires three or more daily insulin injections or an insulin pump, and that the member uses a once-daily long-acting insulin only."
        },
        {
          "claim": "C4",
          "verdict": "supported",
          "explanation": "The POLICY revision history entry for 01/01/2026 states each element of the claim."
        },
        {
          "claim": "C5",
          "verdict": "supported",
          "explanation": "POLICY Criterion I.B.1 states this wording verbatim."
        },
        {
          "claim": "C6",
          "verdict": "supported",
          "explanation": "POLICY Section I says CGM is medically necessary when ALL of Criteria A through E are met."
        },
        {
          "claim": "C7",
          "verdict": "supported",
          "explanation": "NOTES document type 2 diabetes diagnosed in 2009 (E11.65), neuropathy (E11.42) and hypoglycemia (E11.649)."
        },
        {
          "claim": "C8",
          "verdict": "supported",
          "explanation": "NOTES document glargine 32 units nightly, started in 2024 after failure on metformin and empagliflozin, and list code Z79.4."
        },
        {
          "claim": "C9",
          "verdict": "supported",
          "explanation": "NOTES Plan item 1 states this verbatim."
        },
        {
          "claim": "C10",
          "verdict": "supported",
          "explanation": "NOTES document training by a diabetes educator on the visit date, the patient's demonstration of sensor application and app use, and an electronic signature by [PROVIDER_NAME_1]."
        },
        {
          "claim": "C11",
          "verdict": "supported",
          "explanation": "The NOTES header reads 'Telehealth + In-Office Labs' with a visit date of 09/10/2026, and the note covers A1c, hypoglycemia history and insulin regimen. DENIAL gives the request date as 09/18/2026, eight days later. POLICY Criterion I.E requires a visit within 6 months before ordering."
        },
        {
          "claim": "C12",
          "verdict": "supported",
          "explanation": "NOTES list both episodes with these values and times, each symptomatic and self-treated. The chief complaint states two overnight episodes in the past 3 months."
        },
        {
          "claim": "C13",
          "verdict": "supported",
          "explanation": "NOTES state the dose was reduced from 36 to 32 units after the first episode and that the second episode occurred despite the reduction."
        },
        {
          "claim": "C14",
          "verdict": "supported",
          "explanation": "POLICY Criterion I.B.2.a defines this as recurrent level 2 events (glucose < 54 mg/dL)."
        },
        {
          "claim": "C15",
          "verdict": "supported",
          "explanation": "EV-3 states that Table 6.4 defines level 2 hypoglycemia as glucose below 54 mg/dL."
        },
        {
          "claim": "C16",
          "verdict": "supported",
          "explanation": "NOTES report an A1c of 9.1% on 09/10/2026, with a previous value of 8.7% in 03/2026."
        },
        {
          "claim": "C17",
          "verdict": "supported",
          "explanation": "The NOTES assessment states each point, and the HPI documents reduced fingertip sensation."
        },
        {
          "claim": "C18",
          "verdict": "supported",
          "explanation": "NOTES state 'Lives alone.'"
        },
        {
          "claim": "C19",
          "verdict": "supported",
          "explanation": "NOTES Plan items 2 and 3 state this."
        },
        {
          "claim": "C20",
          "verdict": "supported",
          "explanation": "EV-1 states that Rec. 7.15 recommends CGM for adults on insulin therapy (Grade A), and that the wording changed from 'should be offered' in 2024 to 'recommended' in 2026 for adults on basal insulin."
        },
        {
          "claim": "C21",
          "verdict": "supported",
          "explanation": "EV-3 states that CGM is particularly useful for people at risk for hypoglycemia. It also describes looser targets for older adults with complex or intermediate health because hypoglycemia is the greater danger."
        },
        {
          "claim": "C22",
          "verdict": "supported",
          "explanation": "EV-2 states this verbatim."
        },
        {
          "claim": "C23",
          "verdict": "supported",
          "explanation": "DENIAL states the member may request, free of charge, copies of all documents and the clinical criteria used."
        },
        {
          "claim": "C24",
          "verdict": "supported",
          "explanation": "DENIAL lists the reviewer as Plan Medical Director (Internal Medicine)."
        },
        {
          "claim": "C25",
          "verdict": "supported",
          "explanation": "POLICY EOC sections 9.1 and 9.2 give the 30 calendar day and 72 hour timeframes. DENIAL also states the 72-hour expedited timeframe."
        },
        {
          "claim": "C26",
          "verdict": "supported",
          "explanation": "DENIAL names the Oregon Division of Financial Regulation for external review. POLICY section 9.4 confirms external review is available after an upheld internal appeal."
        },
        {
          "claim": "C27",
          "verdict": "supported",
          "explanation": "DENIAL lists this mailing address and fax number for appeals."
        }
      ],
      "untracked_claims": []
    }
  }
  ```

  </details>

- `5:58` **reviewer** · model call · claude-opus-5-5 · effort high · 11,601 in / 3,681 out tokens · 37.7s · $0.1200
- `5:58` **reviewer** ✓ review_1 complete in 37.7s · score 8/10 · revise · 7 insurer rebuttals · 4 required changes

  <details><summary>data</summary>

  ```json
  {
    "stage": "review_1",
    "attempt": 1,
    "duration_s": 37.69,
    "total_duration_s": 37.69,
    "validator": "none",
    "output": {
      "score": 8,
      "decision": "revise",
      "insurer_rebuttals": [
        "Guideline credibility: Section 5 makes very specific claims that are not in the record and that the reviewer can check: 'Recommendation 7.15', 'Grade A', wording 'strengthened from should be offered (2024) to recommended', and a quoted Summary of Revisions finding. If any detail is wrong, the reviewer can use it to discredit the letter. This matters most at external review.",
        "Older-adult targets: the reference to CGM targets for 'older adults with complex or intermediate health' implies the member is in that category. The record does not document a complex or intermediate health classification, so the reviewer can call it unsupported.",
        "Hypoglycemia pathway: Criterion I.B.2.a requires level 2 events that persist despite 'multiple attempts' to adjust medication. Only one dose reduction (36 to 32 units) is documented. A heading that labels the section 'Criterion I.B.2' invites the reviewer to say that pathway is not met and that the letter overstates the record.",
        "Expedited status: the reviewer can decline expedited handling. Both events were self-treated, no level 3 event occurred, and the problem has gone on for months. The provider statement only 'supports' the expedited request and does not attest that the standard timeframe could seriously jeopardize the member's health.",
        "Overstatement: the letter says insulin 'cannot safely be increased further.' The note says hypoglycemia 'limits further insulin titration.' The reviewer can point to the gap between the two.",
        "FDA indication (I.C): the specific CGM device is not named. The reviewer could question whether the device's labeling covers a non-intensive basal-insulin user. This is weak because the prescriber documented 'per FDA labeling', and the record has no device name to add.",
        "Reviewer specialty: the plan documents set no same-specialty reviewer requirement, so the Plan can decline this request without consequence. The draft correctly frames it as a request, so this costs nothing."
      ],
      "required_changes": [
        "Section 5: verify every ADA citation against the published 2026 Standards of Care before signing. Remove the recommendation number, evidence grade, 'strengthened from should be offered (2024)' claim and the Summary of Revisions statement unless the exact text is confirmed. Remove the older-adult 'complex/intermediate health' sentence, or reword it so it does not imply the member is in that category. Shorten the section so it leans mainly on the Plan's own statement that the 01/01/2026 revision aligned MP-DME-031 with national coverage criteria and professional society guidelines.",
        "Section 3: retitle it, for example 'Additional Clinical Support: Recurrent Nocturnal Hypoglycemia', and remove '(Criterion I.B.2)' from the heading. Describe the events as meeting the policy's own level 2 definition (<54 mg/dL), citing the policy rather than the ADA. Do not claim I.B.2.a is fully met, and keep the framing that I.B.1 alone satisfies Criterion I.B.",
        "Section 4: change 'my insulin cannot safely be increased further' to wording that matches the record. For example: 'my endocrinologist documented that nocturnal hypoglycemia limits further insulin titration while my A1c is rising.'",
        "Provider statement: add an explicit expedited certification that tracks the standard in EOC 9.2 and the denial notice, using only facts in the record. For example: 'In my clinical judgment, waiting for the standard 30-day timeframe could seriously jeopardize this patient's health. She has had two documented symptomatic nocturnal glucose readings below 54 mg/dL (48 and 51 mg/dL) despite an insulin dose reduction, she lives alone, fingerstick testing cannot detect overnight lows and is impaired by neuropathy, and her A1c is rising to 9.1%, so her insulin cannot be safely titrated without CGM.'"
      ],
      "strengths": [
        "The core argument is decisive and well documented. It quotes the denial's superseded '3 or more injections or pump' requirement next to the 01/01/2026 revision history and current Criterion I.B.1, showing that the denial's own fact (once-daily basal insulin) satisfies the current policy.",
        "The criterion-by-criterion table covers I.A through I.E with specific dates and record facts. This includes the 09/10/2026 visit falling 8 days before the 09/18/2026 request and the documented training with demonstrated competence.",
        "It correctly treats I.B.1 as sufficient on its own and offers hypoglycemia only as supplementary support.",
        "It requests the applied policy version, the claim file and reviewer credentials, which will expose whether the outdated criteria were used.",
        "It includes a fallback to the 30-day standard pre-service timeline, a reservation of external review rights through Oregon DFR, and the correct appeals address and fax.",
        "The member files directly and the provider co-signs, which avoids the authorized-representative form requirement in EOC 9.3.",
        "Placeholders are preserved, and the enclosures include the current policy and EOC excerpt so the reviewer can verify the revision."
      ]
    }
  }
  ```

  </details>

- `5:58` **reviewer** · score 8/10 · revise · 4 required changes
- `5:58` **reviewer** · insurer would argue: Guideline credibility: Section 5 makes very specific claims that are not in the record and that the reviewer can check: 'Recommendation 7.15', 'Grade A', wording 'strengthened from should be offered (2024) to recommended', and a quoted Summary of Revisions finding. If any detail is wrong, the reviewer can use it to discredit the letter. This matters most at external review.
- `5:58` **reviewer** · insurer would argue: Older-adult targets: the reference to CGM targets for 'older adults with complex or intermediate health' implies the member is in that category. The record does not document a complex or intermediate health classification, so the reviewer can call it unsupported.
- `5:58` **reviewer** · insurer would argue: Hypoglycemia pathway: Criterion I.B.2.a requires level 2 events that persist despite 'multiple attempts' to adjust medication. Only one dose reduction (36 to 32 units) is documented. A heading that labels the section 'Criterion I.B.2' invites the reviewer to say that pathway is not met and that the letter overstates the record.
- `5:58` **reviewer** · insurer would argue: Expedited status: the reviewer can decline expedited handling. Both events were self-treated, no level 3 event occurred, and the problem has gone on for months. The provider statement only 'supports' the expedited request and does not attest that the standard timeframe could seriously jeopardize the member's health.
- `5:58` **reviewer** · insurer would argue: Overstatement: the letter says insulin 'cannot safely be increased further.' The note says hypoglycemia 'limits further insulin titration.' The reviewer can point to the gap between the two.
- `5:58` **reviewer** · insurer would argue: FDA indication (I.C): the specific CGM device is not named. The reviewer could question whether the device's labeling covers a non-intensive basal-insulin user. This is weak because the prescriber documented 'per FDA labeling', and the record has no device name to add.
- `5:58` **reviewer** · insurer would argue: Reviewer specialty: the plan documents set no same-specialty reviewer requirement, so the Plan can decline this request without consequence. The draft correctly frames it as a request, so this costs nothing.
- `5:58` **reviewer** · required change: Section 5: verify every ADA citation against the published 2026 Standards of Care before signing. Remove the recommendation number, evidence grade, 'strengthened from should be offered (2024)' claim and the Summary of Revisions statement unless the exact text is confirmed. Remove the older-adult 'complex/intermediate health' sentence, or reword it so it does not imply the member is in that category. Shorten the section so it leans mainly on the Plan's own statement that the 01/01/2026 revision aligned MP-DME-031 with national coverage criteria and professional society guidelines.
- `5:58` **reviewer** · required change: Section 3: retitle it, for example 'Additional Clinical Support: Recurrent Nocturnal Hypoglycemia', and remove '(Criterion I.B.2)' from the heading. Describe the events as meeting the policy's own level 2 definition (<54 mg/dL), citing the policy rather than the ADA. Do not claim I.B.2.a is fully met, and keep the framing that I.B.1 alone satisfies Criterion I.B.
- `5:58` **reviewer** · required change: Section 4: change 'my insulin cannot safely be increased further' to wording that matches the record. For example: 'my endocrinologist documented that nocturnal hypoglycemia limits further insulin titration while my A1c is rising.'
- `5:58` **reviewer** · required change: Provider statement: add an explicit expedited certification that tracks the standard in EOC 9.2 and the denial notice, using only facts in the record. For example: 'In my clinical judgment, waiting for the standard 30-day timeframe could seriously jeopardize this patient's health. She has had two documented symptomatic nocturnal glucose readings below 54 mg/dL (48 and 51 mg/dL) despite an insulin dose reduction, she lives alone, fingerstick testing cannot detect overnight lows and is impaired by neuropathy, and her A1c is rising to 9.1%, so her insulin cannot be safely titrated without CGM.'
- `5:58` **fact_checker** · 27/27 claims verified · 0 problems
- `5:58` **orchestrator** ⟲ round 1 not approved → back to writer with 4 changes + 0 fact problems

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "writer"
    ],
    "round": 1,
    "fed_back_to_writer": {
      "required_changes": [
        "Section 5: verify every ADA citation against the published 2026 Standards of Care before signing. Remove the recommendation number, evidence grade, 'strengthened from should be offered (2024)' claim and the Summary of Revisions statement unless the exact text is confirmed. Remove the older-adult 'complex/intermediate health' sentence, or reword it so it does not imply the member is in that category. Shorten the section so it leans mainly on the Plan's own statement that the 01/01/2026 revision aligned MP-DME-031 with national coverage criteria and professional society guidelines.",
        "Section 3: retitle it, for example 'Additional Clinical Support: Recurrent Nocturnal Hypoglycemia', and remove '(Criterion I.B.2)' from the heading. Describe the events as meeting the policy's own level 2 definition (<54 mg/dL), citing the policy rather than the ADA. Do not claim I.B.2.a is fully met, and keep the framing that I.B.1 alone satisfies Criterion I.B.",
        "Section 4: change 'my insulin cannot safely be increased further' to wording that matches the record. For example: 'my endocrinologist documented that nocturnal hypoglycemia limits further insulin titration while my A1c is rising.'",
        "Provider statement: add an explicit expedited certification that tracks the standard in EOC 9.2 and the denial notice, using only facts in the record. For example: 'In my clinical judgment, waiting for the standard 30-day timeframe could seriously jeopardize this patient's health. She has had two documented symptomatic nocturnal glucose readings below 54 mg/dL (48 and 51 mg/dL) despite an insulin dose reduction, she lives alone, fingerstick testing cannot detect overnight lows and is impaired by neuropathy, and her A1c is rising to 9.1%, so her insulin cannot be safely titrated without CGM.'"
      ],
      "insurer_rebuttals": [
        "Guideline credibility: Section 5 makes very specific claims that are not in the record and that the reviewer can check: 'Recommendation 7.15', 'Grade A', wording 'strengthened from should be offered (2024) to recommended', and a quoted Summary of Revisions finding. If any detail is wrong, the reviewer can use it to discredit the letter. This matters most at external review.",
        "Older-adult targets: the reference to CGM targets for 'older adults with complex or intermediate health' implies the member is in that category. The record does not document a complex or intermediate health classification, so the reviewer can call it unsupported.",
        "Hypoglycemia pathway: Criterion I.B.2.a requires level 2 events that persist despite 'multiple attempts' to adjust medication. Only one dose reduction (36 to 32 units) is documented. A heading that labels the section 'Criterion I.B.2' invites the reviewer to say that pathway is not met and that the letter overstates the record.",
        "Expedited status: the reviewer can decline expedited handling. Both events were self-treated, no level 3 event occurred, and the problem has gone on for months. The provider statement only 'supports' the expedited request and does not attest that the standard timeframe could seriously jeopardize the member's health.",
        "Overstatement: the letter says insulin 'cannot safely be increased further.' The note says hypoglycemia 'limits further insulin titration.' The reviewer can point to the gap between the two.",
        "FDA indication (I.C): the specific CGM device is not named. The reviewer could question whether the device's labeling covers a non-intensive basal-insulin user. This is weak because the prescriber documented 'per FDA labeling', and the record has no device name to add.",
        "Reviewer specialty: the plan documents set no same-specialty reviewer requirement, so the Plan can decline this request without consequence. The draft correctly frames it as a request, so this costs nothing."
      ],
      "unsupported_claims": [],
      "untracked_claims": []
    }
  }
  ```

  </details>

- `5:58` **writer** ▶ draft_2 (attempt 1/3) · received documents, facts, plan, policy analysis, evidence + the previous draft and the reviewers' feedback
- `7:30` **writer** · model call · claude-opus-5-5 · effort high · 21,586 in / 9,743 out tokens · 92.1s · $0.2812
- `7:30` **writer** ✓ draft_2 complete in 92.1s · 1,359 words · 30 sourced claims · cites DENIAL×10, EV-1×1, NOTES×15, POLICY×9

  <details><summary>data</summary>

  ```json
  {
    "stage": "draft_2",
    "attempt": 1,
    "duration_s": 92.09,
    "total_duration_s": 92.09,
    "validator": "passed",
    "output": {
      "subject_line": "Request for Expedited Internal Appeal: CGM System and Sensors (E2103 / A4239), Claim/Request No. [OTHER_IDENTIFIER_1], Member ID [MEMBER_ID_1]",
      "words": 1359,
      "claims": [
        {
          "id": "C1",
          "text": "The Notice of Adverse Benefit Determination dated September 22, 2026 denied coverage for the CGM system and sensors, HCPCS E2103 / A4239, with reason code MN-04; requesting provider [PROVIDER_NAME_1] (Endocrinology), Willamette Valley Endocrine Associates.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C2",
          "text": "The therapeutic CGM and sensors were prescribed by the member's endocrinologist, [PROVIDER_NAME_1].",
          "sources": [
            "NOTES",
            "DENIAL"
          ]
        },
        {
          "id": "C3",
          "text": "In the past three months the member had two symptomatic overnight episodes with glucose below 54 mg/dL; the second occurred after the insulin dose had been lowered.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C4",
          "text": "The member lives alone.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C5",
          "text": "The endocrinologist documented that fingerstick monitoring is inadequate to detect nocturnal lows and is impaired by neuropathy (reduced fingertip sensation).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C6",
          "text": "The denial notice and EOC Section 9.2 provide for an expedited appeal decided within 72 hours when the standard timeframe could seriously jeopardize the member's life, health, or ability to regain maximum function.",
          "sources": [
            "DENIAL",
            "POLICY"
          ]
        },
        {
          "id": "C7",
          "text": "The denial states MP-DME-031 requires intensive insulin therapy of three or more daily injections or an insulin pump, and that the member uses a once-daily long-acting insulin only.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C8",
          "text": "MP-DME-031's revision history states that on 01/01/2026 Criteria I.B was revised, the requirement for three or more daily insulin injections was removed, and coverage extended to members using any insulin or with documented problematic hypoglycemia.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C9",
          "text": "Current Criterion I.B.1 is met when the member is insulin-treated (any insulin regimen, including a single daily dose of basal/long-acting insulin).",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C10",
          "text": "The CGM request was dated September 18, 2026, more than eight months after the 01/01/2026 revision.",
          "sources": [
            "DENIAL",
            "POLICY"
          ]
        },
        {
          "id": "C11",
          "text": "Section I of MP-DME-031 requires that all of Criteria A through E be met.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C12",
          "text": "The member has type 2 diabetes diagnosed in 2009 (E11.65) with diabetic peripheral neuropathy (E11.42).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C13",
          "text": "The member takes insulin glargine 32 units nightly, started in 2024 after failure to reach goal on metformin and empagliflozin (Z79.4).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C14",
          "text": "The denial acknowledges the member's once-daily long-acting insulin use.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C15",
          "text": "Plan item 1 of the 09/10/2026 note reads: 'Prescribe therapeutic CGM system with sensors (E2103 / A4239) per FDA labeling.'",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C16",
          "text": "A diabetes educator trained the member on 09/10/2026; she demonstrated sensor application and app use; the note is signed by the prescribing endocrinologist.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C17",
          "text": "A telehealth visit with in-office labs on 09/10/2026, eight days before the 09/18/2026 request, evaluated the member's A1c, hypoglycemia history and insulin regimen.",
          "sources": [
            "NOTES",
            "DENIAL"
          ]
        },
        {
          "id": "C18",
          "text": "The policy defines level 2 hypoglycemic events as glucose < 54 mg/dL, and Criterion I.B requires only one of I.B.1 or I.B.2.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C19",
          "text": "Episodes: 07/02/2026 fingerstick 48 mg/dL at 3:10 AM, symptomatic, self-treated; 08/19/2026 fingerstick 51 mg/dL at 2:45 AM, symptomatic, self-treated.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C20",
          "text": "After the first episode the glargine dose was reduced from 36 to 32 units; the second episode occurred despite the reduction.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C21",
          "text": "The endocrinologist diagnosed recurrent nocturnal level 2 hypoglycemia despite insulin dose reduction (E11.649).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C22",
          "text": "Hemoglobin A1c was 9.1% on 09/10/2026, up from 8.7% in 03/2026.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C23",
          "text": "The endocrinologist documented that nocturnal hypoglycemia limits further insulin titration while glycemic control is worsening.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C24",
          "text": "The plan is to use CGM data to safely titrate basal insulin and reduce hypoglycemia risk, with follow-up in 3 months to review CGM data and adherence.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C25",
          "text": "The Plan's revision history states the 01/01/2026 revision of Criteria I.B was made to align with updated national coverage criteria and professional society guidelines.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C26",
          "text": "The ADA Standards of Care in Diabetes—2026, Section 7 (Diabetes Technology), recommend CGM for adults on insulin therapy.",
          "sources": [
            "EV-1"
          ]
        },
        {
          "id": "C27",
          "text": "The denial notice states the member may request, free of charge, copies of all documents and the clinical criteria used, and the notice does not identify which version of MP-DME-031 was applied.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C28",
          "text": "The original determination was reviewed by the Plan Medical Director (Internal Medicine).",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C29",
          "text": "Standard pre-service appeals are decided within 30 calendar days of receipt under EOC Section 9.1.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C30",
          "text": "If the denial is upheld on internal appeal, the member may request independent external review through the Oregon Division of Financial Regulation.",
          "sources": [
            "DENIAL",
            "POLICY"
          ]
        }
      ],
      "citations_per_source": {
        "DENIAL": 10,
        "NOTES": 15,
        "POLICY": 9,
        "EV-1": 1
      },
      "enclosures": [
        "Notice of Adverse Benefit Determination, Evergreen Mutual Health Plan, dated September 22, 2026",
        "Willamette Valley Endocrine Associates progress note dated 09/10/2026",
        "Evergreen Mutual Medical Policy MP-DME-031 (last revised 01/01/2026) and Evidence of Coverage Section 9 excerpt"
      ]
    }
  }
  ```

  </details>

- `7:30` **writer** → reviewer + fact_checker: draft 2 (1359 words, 30 claims)

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "reviewer",
      "fact_checker"
    ],
    "artifact": "AppealDraft",
    "round": 2
  }
  ```

  </details>

- `7:30` **orchestrator** · reviewer and fact checker check draft 2 in parallel
- `7:30` **reviewer** ▶ review_2 (attempt 1/3) · received draft 2, the documents and the policy analysis
- `7:30` **fact_checker** ▶ factcheck_2 (attempt 1/3) · received draft 2's 30 claims and every cited source
- `7:55` **fact_checker** · model call · claude-opus-5-5 · effort medium · 12,041 in / 3,083 out tokens · 25.7s · $0.1098
- `7:55` **fact_checker** ✓ factcheck_2 complete in 25.7s · 30/30 claims verified · 0 unsupported · 1 untracked statements

  <details><summary>data</summary>

  ```json
  {
    "stage": "factcheck_2",
    "attempt": 1,
    "duration_s": 25.66,
    "total_duration_s": 25.66,
    "validator": "none",
    "output": {
      "verified": 30,
      "claims": 30,
      "checks": [
        {
          "claim": "C1",
          "verdict": "supported",
          "explanation": "The denial is dated September 22, 2026. It lists the service as CGM system and sensors E2103/A4239, reason code MN-04, and the requesting provider as [PROVIDER_NAME_1] (Endocrinology), Willamette Valley Endocrine Associates."
        },
        {
          "claim": "C2",
          "verdict": "supported",
          "explanation": "The note's plan prescribes a therapeutic CGM with sensors. The provider is [PROVIDER_NAME_1] (Endocrinology), and the denial confirms this provider requested it."
        },
        {
          "claim": "C3",
          "verdict": "supported",
          "explanation": "The note documents symptomatic nocturnal readings of 48 and 51 mg/dL on 07/02 and 08/19/2026, within 3 months of the 09/10 visit. The second occurred despite the dose reduction."
        },
        {
          "claim": "C4",
          "verdict": "supported",
          "explanation": "The note states 'Lives alone.'"
        },
        {
          "claim": "C5",
          "verdict": "supported",
          "explanation": "The assessment states fingerstick monitoring is inadequate to detect nocturnal lows and is impaired by neuropathy. The HPI documents reduced fingertip sensation."
        },
        {
          "claim": "C6",
          "verdict": "supported",
          "explanation": "Both the denial and EOC 9.2 describe an expedited appeal decided within 72 hours under the jeopardy standard."
        },
        {
          "claim": "C7",
          "verdict": "supported",
          "explanation": "The denial's reason text states this requirement and the member's once-daily long-acting insulin."
        },
        {
          "claim": "C8",
          "verdict": "supported",
          "explanation": "The policy's 01/01/2026 revision-history entry states exactly this."
        },
        {
          "claim": "C9",
          "verdict": "supported",
          "explanation": "Criterion I.B.1 is quoted accurately."
        },
        {
          "claim": "C10",
          "verdict": "supported",
          "explanation": "The denial gives the request date as September 18, 2026. The policy revision is dated 01/01/2026, which is about 8.5 months earlier."
        },
        {
          "claim": "C11",
          "verdict": "supported",
          "explanation": "Section I says 'ALL of the following criteria,' listing A through E."
        },
        {
          "claim": "C12",
          "verdict": "supported",
          "explanation": "The note documents type 2 diabetes diagnosed in 2009 (E11.65) and diabetic peripheral neuropathy (E11.42)."
        },
        {
          "claim": "C13",
          "verdict": "supported",
          "explanation": "The note documents glargine 32 units nightly, started in 2024 after failure on metformin and empagliflozin, with code Z79.4."
        },
        {
          "claim": "C14",
          "verdict": "supported",
          "explanation": "The denial states the member uses a once-daily long-acting insulin only."
        },
        {
          "claim": "C15",
          "verdict": "supported",
          "explanation": "The quote matches Plan item 1 verbatim."
        },
        {
          "claim": "C16",
          "verdict": "supported",
          "explanation": "The note says the patient was trained today by a diabetes educator and demonstrated sensor application and app use. It is electronically signed by [PROVIDER_NAME_1]."
        },
        {
          "claim": "C17",
          "verdict": "supported",
          "explanation": "The note heading is 'Telehealth + In-Office Labs,' dated 09/10/2026, and it evaluates A1c, hypoglycemia and insulin. The denial gives the request date as 09/18/2026, eight days later."
        },
        {
          "claim": "C18",
          "verdict": "supported",
          "explanation": "Policy I.B.2.a defines level 2 as < 54 mg/dL, and I.B requires at least ONE of the listed options."
        },
        {
          "claim": "C19",
          "verdict": "supported",
          "explanation": "The episode details match the note exactly."
        },
        {
          "claim": "C20",
          "verdict": "supported",
          "explanation": "The note states the dose was reduced from 36 to 32 units after the first episode and the second occurred despite the reduction."
        },
        {
          "claim": "C21",
          "verdict": "supported",
          "explanation": "Assessment item 2 matches, including code E11.649."
        },
        {
          "claim": "C22",
          "verdict": "supported",
          "explanation": "The note's labs show A1c 9.1%, with a previous value of 8.7% in 03/2026."
        },
        {
          "claim": "C23",
          "verdict": "supported",
          "explanation": "The assessment states glycemic control is worsening while nocturnal hypoglycemia limits further titration."
        },
        {
          "claim": "C24",
          "verdict": "supported",
          "explanation": "Plan items 2 and 3 match."
        },
        {
          "claim": "C25",
          "verdict": "supported",
          "explanation": "The revision history states the revision was made to align with updated national coverage criteria and professional society guidelines."
        },
        {
          "claim": "C26",
          "verdict": "supported",
          "explanation": "EV-1 Rec. 7.15 recommends CGM for adults on insulin therapy (Grade A)."
        },
        {
          "claim": "C27",
          "verdict": "supported",
          "explanation": "The denial offers free copies of all documents and clinical criteria. It cites MP-DME-031 without a version or effective date."
        },
        {
          "claim": "C28",
          "verdict": "supported",
          "explanation": "The denial states it was reviewed by the Plan Medical Director (Internal Medicine)."
        },
        {
          "claim": "C29",
          "verdict": "supported",
          "explanation": "EOC 9.1 states standard pre-service appeals are decided within 30 calendar days of receipt."
        },
        {
          "claim": "C30",
          "verdict": "supported",
          "explanation": "The denial names the Oregon Division of Financial Regulation for external review, and EOC 9.4 confirms external review is available after an upheld internal appeal."
        }
      ],
      "untracked_claims": [
        "The letter and provider statement repeatedly say fingerstick monitoring 'cannot detect' the member's nocturnal lows. The note says it is 'inadequate to detect' them. 'Cannot detect' slightly overstates the documented finding."
      ]
    }
  }
  ```

  </details>

- `7:59` **reviewer** · model call · claude-opus-5-5 · effort high · 11,774 in / 2,695 out tokens · 28.8s · $0.1010
- `7:59` **reviewer** ✓ review_2 complete in 28.8s · score 9/10 · revise · 5 insurer rebuttals · 4 required changes

  <details><summary>data</summary>

  ```json
  {
    "stage": "review_2",
    "attempt": 1,
    "duration_s": 28.78,
    "total_duration_s": 28.78,
    "validator": "none",
    "output": {
      "score": 9,
      "decision": "revise",
      "insurer_rebuttals": [
        "Expedited status: 'Both lows were self-treated, there is no level 3 event, and the letter claims fingerstick monitoring cannot detect her nocturnal lows. Yet both the 48 and 51 mg/dL readings were captured by fingerstick. We decline expedited handling and will process this as a standard 30-day appeal.' The note actually says fingerstick monitoring is 'inadequate to detect nocturnal lows.' The draft's 'cannot detect,' repeated in the provider-signed certification, overstates the record and invites this attack on credibility.",
        "Outside authority: 'The appeal cites ADA Standards of Care in Diabetes—2026, Section 7, which was not enclosed and is not in the record. We give it no weight.' This does not defeat the appeal, but an inaccurate or unverifiable citation weakens an otherwise airtight letter.",
        "Criterion I.E: 'I.E requires the treating practitioner to have determined that criteria A–D are met. The progress note documents findings but contains no explicit determination statement.' This is weak because the note documents every element. A one-line attestation in the provider statement would close it.",
        "Criterion I.C: 'No specific device is named, so we cannot verify the order matches the device's FDA indications.' This is weak because the note says 'per FDA labeling,' but naming the device would remove the argument.",
        "Merits: no credible rebuttal. The cited 3+ injection/pump requirement was removed effective 01/01/2026, and current I.B.1 expressly covers a single daily basal insulin dose, which the denial itself confirms."
      ],
      "required_changes": [
        "Change 'cannot detect my nocturnal lows' (Request for Expedited Review) and 'Fingerstick monitoring cannot detect her nocturnal lows' (provider certification) to match the note: fingerstick monitoring 'is inadequate to detect nocturnal lows' and is impaired by neuropathy. Optionally add that the episodes occurred in the middle of the night while she lives alone, which is why intermittent fingersticks cannot reliably catch lows.",
        "In Section 5, either delete the ADA Standards of Care 2026 citation or have the human reviewer verify the exact edition, section and recommendation before signing. The Plan's own revision-history statement that I.B was revised to align with national coverage criteria and professional society guidelines is sufficient on its own.",
        "Add one sentence to the provider statement: 'At the 09/10/2026 visit I evaluated her diabetes control and determined that she meets MP-DME-031 Criteria I.A through I.D.' Optionally name the specific CGM device prescribed so I.E and I.C are explicit.",
        "Replace 'In the past three months' with the specific dates (07/02/2026 and 08/19/2026). This avoids a timing quibble, since the letter will be sent after 09/22/2026."
      ],
      "strengths": [
        "The letter leads with the dispositive point. It quotes the 01/01/2026 revision history removing the 3+ injection requirement and current I.B.1 language expressly covering a single daily basal dose, and it shows the denial's sole factual basis now satisfies the criterion.",
        "A criterion-by-criterion table maps each element I.A through I.E to specific documentation in the 09/10/2026 note, with the request dated 8 days after the visit.",
        "It correctly treats the hypoglycemia pathway as supporting only and does not overclaim I.B.2.a, avoiding the 'multiple attempts' gap.",
        "It requests the exact policy version applied, the claim file, and same-specialty review without inventing a plan requirement for specialist review.",
        "The expedited request includes a fallback to the 30-day standard timeline and preserves external review rights through Oregon DFR.",
        "Placeholders are preserved correctly, and the clinical facts (doses, dates, A1c values, codes) match the record."
      ]
    }
  }
  ```

  </details>

- `7:59` **reviewer** · score 9/10 · revise · 4 required changes
- `7:59` **reviewer** · insurer would argue: Expedited status: 'Both lows were self-treated, there is no level 3 event, and the letter claims fingerstick monitoring cannot detect her nocturnal lows. Yet both the 48 and 51 mg/dL readings were captured by fingerstick. We decline expedited handling and will process this as a standard 30-day appeal.' The note actually says fingerstick monitoring is 'inadequate to detect nocturnal lows.' The draft's 'cannot detect,' repeated in the provider-signed certification, overstates the record and invites this attack on credibility.
- `7:59` **reviewer** · insurer would argue: Outside authority: 'The appeal cites ADA Standards of Care in Diabetes—2026, Section 7, which was not enclosed and is not in the record. We give it no weight.' This does not defeat the appeal, but an inaccurate or unverifiable citation weakens an otherwise airtight letter.
- `7:59` **reviewer** · insurer would argue: Criterion I.E: 'I.E requires the treating practitioner to have determined that criteria A–D are met. The progress note documents findings but contains no explicit determination statement.' This is weak because the note documents every element. A one-line attestation in the provider statement would close it.
- `7:59` **reviewer** · insurer would argue: Criterion I.C: 'No specific device is named, so we cannot verify the order matches the device's FDA indications.' This is weak because the note says 'per FDA labeling,' but naming the device would remove the argument.
- `7:59` **reviewer** · insurer would argue: Merits: no credible rebuttal. The cited 3+ injection/pump requirement was removed effective 01/01/2026, and current I.B.1 expressly covers a single daily basal insulin dose, which the denial itself confirms.
- `7:59` **reviewer** · required change: Change 'cannot detect my nocturnal lows' (Request for Expedited Review) and 'Fingerstick monitoring cannot detect her nocturnal lows' (provider certification) to match the note: fingerstick monitoring 'is inadequate to detect nocturnal lows' and is impaired by neuropathy. Optionally add that the episodes occurred in the middle of the night while she lives alone, which is why intermittent fingersticks cannot reliably catch lows.
- `7:59` **reviewer** · required change: In Section 5, either delete the ADA Standards of Care 2026 citation or have the human reviewer verify the exact edition, section and recommendation before signing. The Plan's own revision-history statement that I.B was revised to align with national coverage criteria and professional society guidelines is sufficient on its own.
- `7:59` **reviewer** · required change: Add one sentence to the provider statement: 'At the 09/10/2026 visit I evaluated her diabetes control and determined that she meets MP-DME-031 Criteria I.A through I.D.' Optionally name the specific CGM device prescribed so I.E and I.C are explicit.
- `7:59` **reviewer** · required change: Replace 'In the past three months' with the specific dates (07/02/2026 and 08/19/2026). This avoids a timing quibble, since the letter will be sent after 09/22/2026.
- `7:59` **fact_checker** · 30/30 claims verified · 1 problems
- `7:59` **fact_checker** ! untracked statement: The letter and provider statement repeatedly say fingerstick monitoring 'cannot detect' the member's nocturnal lows. The note says it is 'inadequate to detect' them. 'Cannot detect' slightly overstates the documented finding.
- `7:59` **orchestrator** ⟲ round 2 not approved → back to writer with 4 changes + 1 fact problems

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "writer"
    ],
    "round": 2,
    "fed_back_to_writer": {
      "required_changes": [
        "Change 'cannot detect my nocturnal lows' (Request for Expedited Review) and 'Fingerstick monitoring cannot detect her nocturnal lows' (provider certification) to match the note: fingerstick monitoring 'is inadequate to detect nocturnal lows' and is impaired by neuropathy. Optionally add that the episodes occurred in the middle of the night while she lives alone, which is why intermittent fingersticks cannot reliably catch lows.",
        "In Section 5, either delete the ADA Standards of Care 2026 citation or have the human reviewer verify the exact edition, section and recommendation before signing. The Plan's own revision-history statement that I.B was revised to align with national coverage criteria and professional society guidelines is sufficient on its own.",
        "Add one sentence to the provider statement: 'At the 09/10/2026 visit I evaluated her diabetes control and determined that she meets MP-DME-031 Criteria I.A through I.D.' Optionally name the specific CGM device prescribed so I.E and I.C are explicit.",
        "Replace 'In the past three months' with the specific dates (07/02/2026 and 08/19/2026). This avoids a timing quibble, since the letter will be sent after 09/22/2026."
      ],
      "insurer_rebuttals": [
        "Expedited status: 'Both lows were self-treated, there is no level 3 event, and the letter claims fingerstick monitoring cannot detect her nocturnal lows. Yet both the 48 and 51 mg/dL readings were captured by fingerstick. We decline expedited handling and will process this as a standard 30-day appeal.' The note actually says fingerstick monitoring is 'inadequate to detect nocturnal lows.' The draft's 'cannot detect,' repeated in the provider-signed certification, overstates the record and invites this attack on credibility.",
        "Outside authority: 'The appeal cites ADA Standards of Care in Diabetes—2026, Section 7, which was not enclosed and is not in the record. We give it no weight.' This does not defeat the appeal, but an inaccurate or unverifiable citation weakens an otherwise airtight letter.",
        "Criterion I.E: 'I.E requires the treating practitioner to have determined that criteria A–D are met. The progress note documents findings but contains no explicit determination statement.' This is weak because the note documents every element. A one-line attestation in the provider statement would close it.",
        "Criterion I.C: 'No specific device is named, so we cannot verify the order matches the device's FDA indications.' This is weak because the note says 'per FDA labeling,' but naming the device would remove the argument.",
        "Merits: no credible rebuttal. The cited 3+ injection/pump requirement was removed effective 01/01/2026, and current I.B.1 expressly covers a single daily basal insulin dose, which the denial itself confirms."
      ],
      "unsupported_claims": [],
      "untracked_claims": [
        "The letter and provider statement repeatedly say fingerstick monitoring 'cannot detect' the member's nocturnal lows. The note says it is 'inadequate to detect' them. 'Cannot detect' slightly overstates the documented finding."
      ]
    }
  }
  ```

  </details>

- `7:59` **writer** ▶ draft_3 (attempt 1/3) · received documents, facts, plan, policy analysis, evidence + the previous draft and the reviewers' feedback
- `9:09` **writer** · model call · claude-opus-5-5 · effort high · 21,542 in / 9,327 out tokens · 70.0s · $0.2727
- `9:09` **writer** ✓ draft_3 complete in 70.0s · 1,473 words · 31 sourced claims · cites DENIAL×11, EV-1×1, EV-3×1, NOTES×15, POLICY×9

  <details><summary>data</summary>

  ```json
  {
    "stage": "draft_3",
    "attempt": 1,
    "duration_s": 69.99,
    "total_duration_s": 69.99,
    "validator": "passed",
    "output": {
      "subject_line": "Request for Expedited Internal Appeal: Denial of CGM System and Sensors (E2103 / A4239), Claim/Request No. [OTHER_IDENTIFIER_1], Member ID [MEMBER_ID_1]",
      "words": 1473,
      "claims": [
        {
          "id": "C1",
          "text": "The Notice of Adverse Benefit Determination dated September 22, 2026 denied coverage for a CGM system and sensors, HCPCS E2103 / A4239, with reason code MN-04.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C2",
          "text": "The requesting provider is [PROVIDER_NAME_1] (Endocrinology), Willamette Valley Endocrine Associates, who prescribed a therapeutic CGM.",
          "sources": [
            "DENIAL",
            "NOTES"
          ]
        },
        {
          "id": "C3",
          "text": "Appeals are sent to Evergreen Mutual Health Plan, Appeals and Grievances, PO Box 4415, Portland, OR 97208, fax 1-800-555-0177.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C4",
          "text": "Fingerstick readings were 48 mg/dL at 3:10 AM on 07/02/2026 and 51 mg/dL at 2:45 AM on 08/19/2026. Both episodes were symptomatic and self-treated.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C5",
          "text": "Glargine was reduced from 36 to 32 units after the first episode, and the second episode occurred despite the reduction.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C6",
          "text": "The patient lives alone.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C7",
          "text": "The patient checks fingerstick glucose 3-4 times daily and has difficulty with fingersticks due to reduced fingertip sensation from neuropathy.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C8",
          "text": "The endocrinologist documented that fingerstick monitoring is inadequate to detect nocturnal lows and is impaired by neuropathy.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C9",
          "text": "The denial notice and EOC Section 9.2 provide for an expedited appeal decided within 72 hours when the standard timeframe could seriously jeopardize the member's life, health, or ability to regain maximum function. Neither document requires a level 3 event for expedited handling.",
          "sources": [
            "DENIAL",
            "POLICY"
          ]
        },
        {
          "id": "C10",
          "text": "The denial states MP-DME-031 requires intensive insulin therapy of three or more daily injections or an insulin pump. It states the member uses a once-daily long-acting insulin only.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C11",
          "text": "The MP-DME-031 revision history states that on 01/01/2026 Criteria I.B was revised, the requirement for three or more daily insulin injections was removed, and coverage was extended to members using any insulin or with documented problematic hypoglycemia.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C12",
          "text": "Current Criterion I.B.1 covers members who are insulin-treated under any insulin regimen, including a single daily dose of basal/long-acting insulin.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C13",
          "text": "The CGM request was dated September 18, 2026, more than eight months after the 01/01/2026 revision.",
          "sources": [
            "DENIAL",
            "POLICY"
          ]
        },
        {
          "id": "C14",
          "text": "Section I of MP-DME-031 requires that all of Criteria A through E be met.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C15",
          "text": "The patient has type 2 diabetes diagnosed in 2009 (E11.65) with diabetic peripheral neuropathy (E11.42).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C16",
          "text": "The patient takes insulin glargine 32 units nightly. She started basal insulin in 2024 after failing to reach goal on metformin and empagliflozin (Z79.4).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C17",
          "text": "The denial acknowledges the member's once-daily long-acting insulin use.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C18",
          "text": "Plan item 1 of the note reads: 'Prescribe therapeutic CGM system with sensors (E2103 / A4239) per FDA labeling.'",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C19",
          "text": "The patient was trained on device use by a diabetes educator on 09/10/2026 and demonstrated sensor application and app use. This is documented in the note electronically signed by the endocrinologist.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C20",
          "text": "The 09/10/2026 visit was a telehealth visit with in-office labs, eight days before the 09/18/2026 request. It evaluated A1c, hypoglycemia history and insulin regimen.",
          "sources": [
            "NOTES",
            "DENIAL"
          ]
        },
        {
          "id": "C21",
          "text": "The policy defines level 2 hypoglycemia as glucose < 54 mg/dL.",
          "sources": [
            "POLICY",
            "EV-3"
          ]
        },
        {
          "id": "C22",
          "text": "The endocrinologist diagnosed recurrent nocturnal level 2 hypoglycemia despite insulin dose reduction (E11.649).",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C23",
          "text": "Hemoglobin A1c was 9.1% on 09/10/2026, up from 8.7% in 03/2026.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C24",
          "text": "Nocturnal hypoglycemia limits further insulin titration.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C25",
          "text": "The plan is to use CGM data to safely titrate basal insulin and reduce hypoglycemia risk, with follow-up in 3 months to review CGM data and adherence.",
          "sources": [
            "NOTES"
          ]
        },
        {
          "id": "C26",
          "text": "The 01/01/2026 revision to I.B was made to align with updated national coverage criteria and professional society guidelines.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C27",
          "text": "ADA Standards of Care in Diabetes—2026, Section 7, Recommendation 7.15 recommends CGM for adults on insulin therapy (Grade A), Diabetes Care 49(Suppl 1):S150. This is flagged for human verification.",
          "sources": [
            "EV-1"
          ]
        },
        {
          "id": "C28",
          "text": "The denial states the member may request, free of charge, copies of all documents and the clinical criteria used. It does not identify the version of MP-DME-031 applied.",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C29",
          "text": "The original determination was reviewed by a Plan Medical Director (Internal Medicine).",
          "sources": [
            "DENIAL"
          ]
        },
        {
          "id": "C30",
          "text": "Standard pre-service appeals are decided within 30 calendar days under EOC Section 9.1.",
          "sources": [
            "POLICY"
          ]
        },
        {
          "id": "C31",
          "text": "If the denial is upheld, the member may request independent external review through the Oregon Division of Financial Regulation.",
          "sources": [
            "DENIAL",
            "POLICY"
          ]
        }
      ],
      "citations_per_source": {
        "DENIAL": 11,
        "NOTES": 15,
        "POLICY": 9,
        "EV-3": 1,
        "EV-1": 1
      },
      "enclosures": [
        "Notice of Adverse Benefit Determination, Evergreen Mutual Health Plan, dated September 22, 2026",
        "Willamette Valley Endocrine Associates progress note dated 09/10/2026",
        "Evergreen Mutual Medical Policy MP-DME-031 (last revised 01/01/2026) and Evidence of Coverage Section 9 excerpt"
      ]
    }
  }
  ```

  </details>

- `9:09` **writer** → reviewer + fact_checker: draft 3 (1473 words, 31 claims)

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "reviewer",
      "fact_checker"
    ],
    "artifact": "AppealDraft",
    "round": 3
  }
  ```

  </details>

- `9:09` **orchestrator** · reviewer and fact checker check draft 3 in parallel
- `9:09` **reviewer** ▶ review_3 (attempt 1/3) · received draft 3, the documents and the policy analysis
- `9:09` **fact_checker** ▶ factcheck_3 (attempt 1/3) · received draft 3's 31 claims and every cited source
- `9:31` **reviewer** · model call · claude-opus-5-5 · effort high · 12,061 in / 2,097 out tokens · 22.4s · $0.0902
- `9:31` **reviewer** ✓ review_3 complete in 22.5s · score 9/10 · approve · 6 insurer rebuttals · 0 required changes

  <details><summary>data</summary>

  ```json
  {
    "stage": "review_3",
    "attempt": 1,
    "duration_s": 22.45,
    "total_duration_s": 22.45,
    "validator": "none",
    "output": {
      "score": 9,
      "decision": "approve",
      "insurer_rebuttals": [
        "Expedited status is not warranted: both lows were level 2, self-treated, with no third-party help, and the patient has managed on fingersticks for months. The plan could process this as a standard 30-day appeal. This affects only the timing, not the merits, and the draft already asks for the standard 30-day decision as a fallback.",
        "Criterion I.C (FDA indications) cannot be verified because the record does not name the device brand or model. The draft handles this with a prescriber-completed 'CGM system prescribed' line. It needs to be filled in before sending.",
        "The hypoglycemia pathway (I.B.2.a) is not met because only one medication adjustment is documented, not 'multiple attempts.' The draft avoids this by calling the episodes 'additional clinical support' and relying on I.B.1, so the rebuttal does not reach the outcome.",
        "The plan has no requirement for a same-specialty reviewer. The draft correctly frames this as a request rather than an entitlement, so there is little to rebut.",
        "The ADA citation (Rec 7.15, page S150) could be challenged if it does not match the published text. It is not needed to win, and the draft already flags it for verification or deletion before signing.",
        "A version or date-of-service argument fails because the 01/01/2026 revision predates both the 09/10/2026 visit and the 09/18/2026 request. Realistically, the plan has no viable merits defense under current MP-DME-031."
      ],
      "required_changes": [],
      "strengths": [
        "The draft leads with the decisive point: the denial applied the 3+ injections/pump requirement that the MP-DME-031 revision history states was REMOVED effective 01/01/2026. It quotes both the revision history and current I.B.1 language covering a single daily basal dose.",
        "It turns the denial's own stated fact (once-daily long-acting insulin) into proof that I.B.1 is met.",
        "A criterion-by-criterion table maps I.A through I.E to specific documentation in the 09/10/2026 note, so the reviewer has nothing left to deny under Section I.",
        "The hypoglycemia evidence is presented accurately and is not overclaimed. The draft does not assert I.B.2.a is met despite only one dose adjustment being documented, and it does not claim any level 3 event.",
        "The treating endocrinologist's statement documents the determination that I.A through I.D are met (supporting I.E), certifies the expedited request, and leaves the device name for the prescriber to fill in. No facts are invented.",
        "It requests the specific MP-DME-031 version applied, the claim file, and reviewer credentials, which builds a record for external review if needed.",
        "It correctly sets out the 72-hour expedited and 30-day standard timeframes and reserves the right to external review through the Oregon Division of Financial Regulation.",
        "The patient signs as the member, so no Appointment of Representative form is needed. Placeholders are preserved exactly, and the unverified guideline citation is clearly flagged for the human reviewer."
      ]
    }
  }
  ```

  </details>

- `9:31` **fact_checker** · model call · claude-opus-5-5 · effort medium · 12,389 in / 2,778 out tokens · 22.6s · $0.1051
- `9:31` **fact_checker** ✓ factcheck_3 complete in 22.6s · 31/31 claims verified · 0 unsupported · 0 untracked statements

  <details><summary>data</summary>

  ```json
  {
    "stage": "factcheck_3",
    "attempt": 1,
    "duration_s": 22.64,
    "total_duration_s": 22.66,
    "validator": "none",
    "output": {
      "verified": 31,
      "claims": 31,
      "checks": [
        {
          "claim": "C1",
          "verdict": "supported",
          "explanation": "The denial is dated September 22, 2026, denies the CGM system and sensors (HCPCS E2103 / A4239), and lists reason code MN-04."
        },
        {
          "claim": "C2",
          "verdict": "supported",
          "explanation": "The denial names [PROVIDER_NAME_1] (Endocrinology), Willamette Valley Endocrine Associates as the requesting provider. Plan item 1 of the note prescribes a therapeutic CGM."
        },
        {
          "claim": "C3",
          "verdict": "supported",
          "explanation": "The denial gives this exact appeals address and fax number."
        },
        {
          "claim": "C4",
          "verdict": "supported",
          "explanation": "The note documents both readings with these dates and times, each symptomatic and self-treated."
        },
        {
          "claim": "C5",
          "verdict": "supported",
          "explanation": "The note states glargine was reduced from 36 to 32 units after the first episode and the second occurred despite the reduction."
        },
        {
          "claim": "C6",
          "verdict": "supported",
          "explanation": "The note states 'Lives alone.'"
        },
        {
          "claim": "C7",
          "verdict": "supported",
          "explanation": "The HPI documents fingerstick checks 3-4 times daily and difficulty due to reduced fingertip sensation from neuropathy."
        },
        {
          "claim": "C8",
          "verdict": "supported",
          "explanation": "The assessment states fingerstick monitoring is inadequate to detect nocturnal lows and is impaired by neuropathy."
        },
        {
          "claim": "C9",
          "verdict": "supported",
          "explanation": "Both the denial and EOC 9.2 describe a 72-hour expedited appeal under this jeopardy standard. Neither mentions a level 3 event requirement."
        },
        {
          "claim": "C10",
          "verdict": "supported",
          "explanation": "The denial's reason section states both points."
        },
        {
          "claim": "C11",
          "verdict": "supported",
          "explanation": "The 01/01/2026 entry in the revision history says exactly this."
        },
        {
          "claim": "C12",
          "verdict": "supported",
          "explanation": "Criterion I.B.1 text matches the claim."
        },
        {
          "claim": "C13",
          "verdict": "supported",
          "explanation": "The denial lists the request date as September 18, 2026. The policy revision was 01/01/2026, about 8.5 months earlier."
        },
        {
          "claim": "C14",
          "verdict": "supported",
          "explanation": "Section I says ALL of the following criteria must be met, A through E."
        },
        {
          "claim": "C15",
          "verdict": "supported",
          "explanation": "The note documents type 2 diabetes diagnosed 2009 (E11.65) and diabetic peripheral neuropathy (E11.42)."
        },
        {
          "claim": "C16",
          "verdict": "supported",
          "explanation": "The note documents glargine 32 units nightly, started in 2024 after failure on metformin and empagliflozin, with code Z79.4."
        },
        {
          "claim": "C17",
          "verdict": "supported",
          "explanation": "The denial states the member uses a once-daily long-acting insulin only."
        },
        {
          "claim": "C18",
          "verdict": "supported",
          "explanation": "The quote matches Plan item 1 of the note."
        },
        {
          "claim": "C19",
          "verdict": "supported",
          "explanation": "The note says the patient was trained 'today' (09/10/2026) by a diabetes educator and demonstrated sensor application and app use. The note is electronically signed by the provider."
        },
        {
          "claim": "C20",
          "verdict": "supported",
          "explanation": "The note header reads 'Telehealth + In-Office Labs', the visit date is 09/10/2026, and the note addresses A1c, hypoglycemia history and the insulin regimen. The request date of 09/18/2026 is eight days later."
        },
        {
          "claim": "C21",
          "verdict": "supported",
          "explanation": "Policy I.B.2.a defines level 2 as glucose < 54 mg/dL, consistent with EV-3."
        },
        {
          "claim": "C22",
          "verdict": "supported",
          "explanation": "Assessment item 2 states this diagnosis with code E11.649."
        },
        {
          "claim": "C23",
          "verdict": "supported",
          "explanation": "The labs show A1c 9.1% on 09/10/2026, with a previous value of 8.7% in 03/2026."
        },
        {
          "claim": "C24",
          "verdict": "supported",
          "explanation": "The assessment states nocturnal hypoglycemia limits further insulin titration."
        },
        {
          "claim": "C25",
          "verdict": "supported",
          "explanation": "Plan items 2 and 3 state this."
        },
        {
          "claim": "C26",
          "verdict": "supported",
          "explanation": "The revision history states the change was made to align with updated national coverage criteria and professional society guidelines."
        },
        {
          "claim": "C27",
          "verdict": "supported",
          "explanation": "EV-1 states Rec 7.15 recommends CGM for adults on insulin therapy (Grade A) and gives the citation Diabetes Care 49(Suppl 1):S150. The claim is appropriately flagged for human verification."
        },
        {
          "claim": "C28",
          "verdict": "supported",
          "explanation": "The denial offers free copies of all documents and clinical criteria. It cites MP-DME-031 without giving a version or effective date."
        },
        {
          "claim": "C29",
          "verdict": "supported",
          "explanation": "The denial states it was reviewed by the Plan Medical Director (Internal Medicine)."
        },
        {
          "claim": "C30",
          "verdict": "supported",
          "explanation": "EOC 9.1 states standard pre-service appeals are decided within 30 calendar days."
        },
        {
          "claim": "C31",
          "verdict": "supported",
          "explanation": "The denial names the Oregon Division of Financial Regulation for external review. EOC 9.4 is consistent with this."
        }
      ],
      "untracked_claims": []
    }
  }
  ```

  </details>

- `9:31` **reviewer** · score 9/10 · approve · 0 required changes
- `9:31` **reviewer** · insurer would argue: Expedited status is not warranted: both lows were level 2, self-treated, with no third-party help, and the patient has managed on fingersticks for months. The plan could process this as a standard 30-day appeal. This affects only the timing, not the merits, and the draft already asks for the standard 30-day decision as a fallback.
- `9:31` **reviewer** · insurer would argue: Criterion I.C (FDA indications) cannot be verified because the record does not name the device brand or model. The draft handles this with a prescriber-completed 'CGM system prescribed' line. It needs to be filled in before sending.
- `9:31` **reviewer** · insurer would argue: The hypoglycemia pathway (I.B.2.a) is not met because only one medication adjustment is documented, not 'multiple attempts.' The draft avoids this by calling the episodes 'additional clinical support' and relying on I.B.1, so the rebuttal does not reach the outcome.
- `9:31` **reviewer** · insurer would argue: The plan has no requirement for a same-specialty reviewer. The draft correctly frames this as a request rather than an entitlement, so there is little to rebut.
- `9:31` **reviewer** · insurer would argue: The ADA citation (Rec 7.15, page S150) could be challenged if it does not match the published text. It is not needed to win, and the draft already flags it for verification or deletion before signing.
- `9:31` **reviewer** · insurer would argue: A version or date-of-service argument fails because the 01/01/2026 revision predates both the 09/10/2026 visit and the 09/18/2026 request. Realistically, the plan has no viable merits defense under current MP-DME-031.
- `9:31` **fact_checker** · 31/31 claims verified · 0 problems
- `9:31` **orchestrator** ✓ draft 3 approved by reviewer and fact checker

  <details><summary>data</summary>

  ```json
  {
    "round": 3,
    "rule": "reviewer approves with score ≥ 8 and the fact checker finds 0 problems"
  }
  ```

  </details>

- `9:31` **orchestrator** · verdict: strong (planner strong, policy analyst strong, reviewer 9/10)
- `9:31` **orchestrator** → packager: draft 3, review, fact check and verdict strong

  <details><summary>data</summary>

  ```json
  {
    "to": [
      "packager"
    ],
    "artifact": "final draft + reviews",
    "round": 3
  }
  ```

  </details>

- `9:31` **packager** ▶ package (attempt 1/3) · received the final draft, reviews and verdict (no model call)
- `9:31` **packager** ✓ package complete in 0.0s

  <details><summary>data</summary>

  ```json
  {
    "stage": "package",
    "attempt": 1,
    "duration_s": 0.03,
    "total_duration_s": 0.05,
    "validator": "none",
    "output": {
      "chars": 170
    }
  }
  ```

  </details>

- `9:31` **packager** · verdict strong · appeal deadline 2027-03-21 · wrote runs/cgm-full-lifecycle/output/appeal_packet.md, runs/cgm-full-lifecycle/output/appeal_packet.html
- `9:31` **orchestrator** ✓ appeal packet ready: runs/cgm-full-lifecycle/output/appeal_packet.html

  <details><summary>data</summary>

  ```json
  {
    "packet": true,
    "verdict": "strong",
    "rounds": 3
  }
  ```

  </details>

- `9:31` **orchestrator** · run summary · done · 572s this session · 15 model calls · 356,521 in / 70,568 out tokens · est. $2.90 · 3 retries
